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            SYNOPSIS
A brief summary of the work incorporated in the thesis with the title
“DISCOVERING THE NEW CHEMICAL ENTITIES OF THERAPEUTIC INTEREST
“has been described as under.
[A]  STUDIES ON PYRAZOLES
[B]  STUDIES ON MICROWAVE INDUCED SYNTHESIS OF
        PYRAZOLINES
[A] STUDIES ON PYRAZOLES
The research on the chemistry of pyrazoles has been a focus of attention for
chemists for a long time, due to their wide spread diversified biological activities like
antitubercular, antimicrobial, hypnotics, anti-inflammatory, antitumor, plant growth regulators
and are also used as herbicidal and fungicidal.
Considering the increasing importance of pyrazole nucleus, the synthesis of some
new chalcones, pyrazolines, cyanopyridines, thiazolidinones, pyrimidinones, isoxazoles,
cyanopyridones, imidazolinones and nitriles has been undertaken in order study their
pharmacological profile .
PART-I: STUDIES ON PYRAZOLYLPYRAZOLINES
Pyrazoline derivatives represent one of the modest class of compounds possessing
wide range of pharmacological activities like anticancer, anthalmentic, antitubercular and
anti-inflammatory etc. With a view to evaluate pharmacological profile, some new
pyrazolines bearing 1-phenyl-3-fluorophenyl-4-formyl pyrazole moiety have been prepared
which have been describes as under.
SECTION – I     : Synthesis and biological evaluation of 1-Aryl-3-[1’,N-phenyl-
       3’-p-fluorophenyl-pyrazol-4’-yl]-2-propene-1-ones.
N
N
F
O
R
Type (I)                  R=Aryl
1
The chalcones of type (I) have been prepared by the condensation of 1-phenyl-3-
p-fluorophenyl-4-formyl pyrazole with different aryl ketones in presence of 40% KOH.
SECTION – II   : Synthesis and biological evaluation of 3-Aryl-5-[1’,N-phenyl-3’-
      p-fluorophenyl-pyrazol-4’-yl]-pyrazolines.
R
N
NH
N
N
F
        Type (II)               R= Aryl
The pyrazoline derivatives of type (II) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate.
SECTION – III  : Synthesis and biological evaluation of 1,N-phenyl-3-aryl-5-[1’,N-
      phenyl-3’-p-fluorophenyl-pyrazol-4’-yl]-pyrazolines.
R
N
N
N
N
F
     Type (III)                      R=Aryl
The pyrazolines of type (III) have been prepared by the reaction of chalcones of
type (I) with phenyl hydrazine in presence of basic catalyst like piperidine.
2
PART-II :   STUDIES ON CYANOPYRIDINES
The compounds containing the cyanopyridine ring system have a prominent feature
in medicinal chemistry and possess biological activities such as antihypertansive,
antibacterial, antidiabetic and anticholestemic. They have been also used as dyes for
cotton and polyester fabrics. In view of these facts, it was contemplated to synthesize
cyanopyridine derivatives, which have been described as under.
SECTION - I  : Synthesis and biological evaluation of 2-Amino–3-cyano – 4 –[1’,N-
  phenyl-3’-p– fluorophenyl– pyrazol– 4’-yl]–6-aryl–pyridines.
       
RN
N
N N
F
NH2
Type (IV)      R=Aryl
2- Amino –3- cyano pyridines of type (IV) have been prepared by the condensation
of chalcones of type (I) with ammonium acetate and malononitrile.
SECTION- II  : Synthesis and biological evaluation of 2- Methoxy –3-cyano-4-[1’,
   N- phenyl-3’- p-fluorophenyl –pyrazol –4’- yl] –6-aryl- pyridines.
RN
N
O
CH3
N N
F
Type (V)          R = Aryl
3
2- Methoxy-3-cyanopyridines of type (V) have been prepared by the condensation
of chalcones of type (I) with malononitrile and sodium methoxide.
PART-III : STUDIES ON THIAZOLIDINONES
It has been reported that compounds bearing thiazolidinones nucleus show wide
range of biological activities such as antitumor, antileprosy, antitubercular and  antibacterial
etc. By considering these valid observations, we have synthesized some new 5-arylidine-
4-thiazolidinones shown as under.
SECTION – I  : Synthesis and biological evaluation of 2-Arylimino–3,N-aryl –5 –
[1’,N- phenyl-3’-p– fluorophenyl– 4’-pyrazolyl methino]–4’-thiazolidinones.
R
R
N N
F
N
S
N
O
  Type (VI)           R = Aryl
The thiazolidinones of type (VI) have been prepared by condensation of 1, N-phenyl-
3-p-fluorophenyl-4-formyl-pyrazole with different thiazolidinones in glacial acetic acid.
PART-IV:  STUDIES ON PYRIMIDINONES
Pyrimidinones possess remarkable pharmaceutical importance and biological
activity. Some of the pyrimidinones, which occurs as natural products like nucleic acid
and vitamin-B can be used as therapeutic agents for treatment of AIDS and antitumor
agent. Keeping in association of pyrimidinones with varied biological activity, it was thought
worthwhile to synthesize new pyrimidinones as under.
SECTION –I  : Synthesis and biological evaluation of 6-Arylimino–7,N-aryl –2-oxo
   –4-[1’,N- phenyl-3’-p– fluorophenyl–pyrazol- 4’-yl]-1,2,3,4-tetrahydro
  thiazolidino-[ 4,5-d ]-pyrimidines.
4
RN
R
N N
F
N
N O
S
N
H
H
′
Type (VII)         R=Aryl
The compounds of type (VII) have been synthesized by the condensation of type
(VI) with urea in presence of hydrochloric acid as catalyst.
PART-V:  STUDIES ON ISOXAZOLES
It has been reported that isoxazole derivatives possess remarkable
pharmacological importance and biological activities such as antifungal, antibacterial,
sedative and hypnotics etc. In order to develop medicinally important compounds, we
have synthesized some new isoxazole derivatives shown as under.
SECTION – I  :  Synthesis and biological evaluation of 3-Aryl-5-[1’,N- phenyl-3’-p–
    fluorophenyl– pyrazol– 4’-yl]–isoxazoles.
R
N
O
N
N
F
Type (VIII)         R = Aryl
The isoxazole derivatives of type (VIII) have been prepared by the reaction of
chalcones of type (I) with anhydrous sodium acetate and hydroxylamine hydrochloride in
glacial acetic acid.
5
PART-VI:  STUDIES ON CYANOPYRIDONES
Cyanopyridones play an important role owing to their wide range of biological
activities such as analgesic, antidiabatic, anticonvulsant, insecticidal and antibacterial
etc. It appeared of interest to design and synthesize cyanopyridone derivatives, which
have been described as under.
SECTION – I  : Synthesis and biological evaluation of 3-Cyano – 4 – [1’, N- phenyl-
   3’-p– fluorophenyl– pyrazol– 4’-yl]–6-aryl–1, 2-dihydro-2-pyridones.
RN
H
N
N N
F
O
                                                                  Type (IX)       R = Aryl
The cyanopyridones of type (IX) have been prepared by the condensation of
chalcones of type (I) with ethylcyanoacetate and ammonium acetate.
PART- VII:  STUDIES ON IMIDAZOLINONES
Imidazolinone derivatives have been found to be potent drug in pharmaceutical
and possess a wide range of biological activities such as anticonvulsant, sedative, hypnotic,
anti-inflammatory, antihistamine and antithyroid etc. In order to develop medicinally
important compounds, we have synthesized some new imidazolinones shown as under.
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SECTION – I  : Synthesis and biological evaluation of 1, N-Aryl-2-alkyl/aryl-4-
    [1’,N- phenyl-3’-p– fluorophenyl– pyrazol– 4’-yl]–imidazolin-5-
   ones.
R'
R''
N N
F
N
N
O
Type (X)                 R’ =Alkyl/Aryl
                                                                               R” =Aryl
The imidazolinone derivatives of type (X) have been prepared by the condensation
of azalactone with different aryl amines in pyridine.
PART-VIII: STUDIES ON NITRILES
Recently nitrile derivatives have drawn considerable attention due to their good
pharmacological activities like cardiovascular, sedative, antifungal and antibacterial etc.
Led by these considerations, we have synthesized some new nitriles, which have been
described as under.
SECTION – I  : Synthesis and biological evaluation of á–Arylamino-[1’,N- phenyl-
    3’-p– fluorophenyl– pyrazol– 4’-yl]–acetonitriles
R
N N
F
N
NH
Type (XI)             R = Aryl
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The nitriles of type (XI) have been prepared by the condensation of 1,N-phenyl-3-
p-fluorophenyl-4-formyl-pyrazole with different aromatic amines in the presence of sodium
cyanide and glacial acetic acid at 0-5 0 C.
[B] STUDIES ON MICROWAVE INDUCED SYNTHESIS OF PYRAZOLINES
In recent years MORE (Microwave Induced Organic Reaction Enhancement)
technique has become very popular due to substantial reduction in reaction time,
operational simplicity and formation of cleaner reaction products. Keeping these facts in
view, we have synthesised acetyl pyrazoline derivatives using microwave irradiation and
also by conventional method.
SECTION – I  : Synthesis and biological evaluation of 1,N-Acetyl- 3-aryl-5-[1’,N-
    phenyl-3’-p-fluorophenyl-pyrazol-4’-yl]-pyrazolines using conve-
    ntional method.
R
N
N
N
N
F
O
CH3
 Type (XII)      R=Aryl
The pyrazoline derivatives of type (XII) have been investigated by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid.
SECTION – II  : Synthesis and biological evaluation of 1,N-Acetyl- 3-aryl-5-[1’,N-
     phenyl-3’-p-fluorophenyl-pyrazol-4’-yl]-pyrazolines by Microwave
     induced synthesis.
R
N
N
N
N
F
O
CH3
Type (XIII)           R=Aryl
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The pyrazoline derivatives of type (XIII) have been synthesized by the reaction of
chalcones of type (I) with hydrazine hydrate in glacial acetic acid under microwave
irradiation in few minutes.Benefits of microwave irradiation have been discussed.
The constitution of newly synthesised compounds have been characterized using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by thin
layer chromatography.
In Vitro study on multiple biological activities:
(1) All the compounds have been evaluated for their antibacterial activity towards Gram
positive and Gram negative bacterial strain and antifungal activity towards
Aspergillus Niger at a concentration of 40 ìg. The biological activity of the
synthesized compounds has been compared with standard drugs.
(2) Selected compounds have been evaluated for their in vitro biological assay like
antitubercular activity towards a strain of Mycobacterium tuberculosis H37 RV at
a concentration of 6.25 ìg/ml using Rifampin as  standard drug, which have been
tested at Tuberculosis Antimicrobial Acquisition Coordinating Facility (TAACF),
Alabama, U.S.A...
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 DISCOVERING THE
  NEW  CHEMICAL
ENTITIES OF
  THERAPEUTIC
INTEREST
Medicinal chemistry concerns the discovery, the development, the
identification of action of biologically active compound at the molecular level.
Emphasis it put on drugs, but the interest of the medicinal chemistry is also
concerned with the study, identification, and synthesis of the metabolic products
of drugs and related compounds.
Medicinal chemistry is a part of pharmacology, this latter taken in its
etymological sense 'pharmakon' + 'logs' : study of drugs. The activity of a given
drug depends on a sequence of physio-chemical events that begin when the active
molecule penetrates into the living organism and which culminates when the
active molecule reaches its target and elicits the appropriate biological response.
Classically it is addmitted that three characteristic phases govern the biological
activity of a drug in a living organism. They are as under.
(I) The pharmaceutical phase
Sometimes it is also called biopharmaceutical phase, deals with the choice
of the appropriate route of administrat ion and with the choice of the
pharmaceutical formulation most suited to the desired medical treatment.
(II) The pharmacokinetic phase
It controls the different parameters that govern the random walk of the drug
between its application point and its final site of action and which ensure the
destruction and/or the elimination once the effect is produced.
(III) The pharmacodynamic phase
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It is the phase of the greatest interest to the medicinal chemist as it deals
with the nature and the quality of the interaction of the drug with its biological
target.
Modern medicinal chemistry began in the 1950s when organic chemists
began to apply newly developed steric & electronic structure active relactionship
of the steroids. During the second half of the twentieth century, chemistry and
biology made possible the discovery of a steady stream of important new
medicines. Chemistry contributed to these discoveries through impactful
advantaces in both theory & practice of this art/science. Notable examples include
invaluable advances in physical measurements, computational techniques,
inorganic catalysis, stereochemical control of synthesis & the application of
physical organic chemical concepts, typified by the transition state analog
principle, to enzyme inhibitor design. At the same time biology continued to
contribute through the discoveries of new concepts and understanding at a rate
that may well be termed explosive.
During the 1970s, target validation became an important consideration in
the selection of therapeutic programs explored by the pharmaceutical industry.
In the strictest sense this strategy holds that intervention in any particular
biochemical or pharmacological pathway has been fully validated only if it has
been shown to work in human subjects. Any research program that does not pass
this definitive test is there for thought to be a 'long shot'. In practise, this leads to
the conclusion that a conservation porfolio of an organization's programs should
strike some appropriate balance between' validated' and 'long shot' targets. In
recent years succesful use of antibodies in neutralizing a target protein or other
substance has come to the accepted as adequate validation; this is also the case
for another validated technology, the use of 'knock-out' or 'knock-in' mice.
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Inspite of all the qualified successes of synthetic drug research achieved in
the last four decades to combat infectious disease of the more than 80,000
different ailments, unfortunately only about one third can be treated with drugs,
most of them only symptomatically. The discovery of better, effective and safey
drugs is needed to fight the cause of dreadful disease like cancer, acquired-
immuno-deficiency-syndrome (AIDS), arthritis, cardiovascular diseases, disorders
of the central nervous system (CNS) such as Alzheimer's disease and other vital
infectious and metabolic disease like rheumatoid arthritis.
In order to meet these challenges one needs to adopt novel approaches in
pharmaceutical research. Both molecular biology and genetic engineering will
be exploited duly in opening up new routes.
It is earnestly believed that towards the begining of new century (2001 AD)
keeping in view the tremendous global technological competition, one is left with
no other choice than to international ize research and development of
pharmaceutical drugs to achieve the common objective "better drugs for a better
word".
AIMS AND OBJECTIVES
Taking in view of the applicability of heterocylic compounds, we have
undertaken the preparation of heterocycles bearing pyrazole nucleus. The
placement of a wide variety of substituents of these nuclei have been designed
in order to evaluate the synthesised products for their pharmacological profile
against several strains of bacteria and fungi.
v To generate several derivatives like chalcones, pyrazolines, cyanopyridones,
th iazo l id inones ,  oxo-pyr imid ines ,  i soxazo les ,  cyanopyr idones ,
imidazolinones, nitriles bearing pyrazole moiety.
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v To synthesise  biologically active pyrazolines bearing pyrazole moiety using
microwave induce synthesis method.
v In a programmed research directed towards the construction of medicinally
active new heterocycles bearing pyrazole has been investigated in following
parts.
v To characterise these products for stucture elucidation using spectroscopic
technique like IR, PMR and Mass spectral studies.
v Purity of all compounds have been checked by thin layer chromatography.
v To evaluate new product for better drug potential against different strains of
bacteria, fungi and for antitubercular activity against Mycobacterium
Tuberculosis H37 Rv.
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[ A ]
STUDIES ON
PYRAZOLE
INTRODUCTION
The pyrazole ring system (Ia) is consisting of three carbon atoms and two
adjacent nitrogen atoms. The ring system does not occur naturally.  Knorr1,2 first
syntehsised a compound (Ib) containing this system in 1833 by a reaction of
ethylacetoacetate with phenylhydrazine. Pyrazoles have been extensively
explored for their applications in the field of medicine, agriculture and industrial
chemistry.
SYNTHETIC ASPECTS
Different methods of preparation are available in literature which are as
under.
1. By the reaction of the substi tuted hydrazines, with 1,3-dicarbonyl
compounds yielded two structurally isomeric pyrazole3.
2. By the reaction of acetylene with diazomethane4.
(Ia)
O
R
O
R2
R1 + NH2 NH
Ar N
N
R1
R2
Ar
R
+ N
N
R1 R2
R
Ar
+ H2O
CH CH + CH2 N
+ N-
N
NH
(Ib)
N
H
N
N
N
C6H5
O
CH3
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3. By the reaction of 1,3-dinitro alkanes with hydrazines5.
4. By the reaction of acetonitrile derivatives with dimethylformamide & diethyl
acetal (DMF-DMA) in xylene gives an intermediate which on reaction with
hydrazine hydrate or phenyl hydrazine in presence of HCl as catalyst yields
pyrazole6.
5. By the reaction of hydrazones with Vilsmeier reagent (DMF-POCl3)
7.
6. By the reaction of 2-formyl glycals with aryl hydrazines under solvent free
conditions give optically pure 4-substituted pyrazoles8.
R1
NO2
R2
+
NO2
R3
NO2NO2
R3
R2
R1
NH2 NH
R4
NN
R4
R3
R2
R1
R
N
DMF-DMA
R
NMe2
N
NH2 NH2
N
NH
NH2R
Ph.NH.NH2
N
N
NH2R
Ph
N NH
CH3
H5C2O2C
C6H3(NO2)2
DMF-POCl3
70-80  C, 4ho
NN
OHC
C6H3(NO2)2
H5C2O2C
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O
OH
OR'
R'O
O
R'O
+ R.NH.NH2
Microwave
irradiation N
N
H
R
H OR'
OR'
OR'
OH
7. By the cyclocondensation of mono substituted hydrazines with enaminones
afforded pyrazoles9.
THERAPEUTIC IMPORTANCE
Pyrazole and its derivatives are shown to possess important biological and
pharmaceutical activities. Pyrazole motifs in drug candidates with good
pharmacological activities are listed below.
R
O
R1
NR2
R3-NH-NH2
N N
R3
R2
R
or / and
N N
R3
R
R2
NN
F3C
CH3
SO2NH2
Celecoxib
[COX-2, inhibitior drug]10
Doramapimod (BIRB796)
[P38MAP-Kinase inhibitor]11
N
N
N N
N N Ar
[Antitumor Agent]12
N
N
N
O
CH3
CH3
CF3
NN
NH
CH3
CH3
CH3CH3
NH
O
O
N O
[Diabetic Agent]13
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Several biological activities associated with pyrazole derivatives have been
described as under.
1. Antitumor14
2. Herbicidal15
3. CNS depressant16
4. Antiulcer17
5. Anticancer18
6. Antimicrobial19
7. Neurotonsin receptor20
8. AntiHIV21
9. Antiviral22
10. Immuno suppresants23
Jonh M. et. al.24 have synthesised pyrazole as neoplasm inhibitors. Antonio
Bellotti25 has reported pyrazole derivatives as antitubercular & bacteriostatic
agents. L. Villa & co-workers26 have screened pyrazoles which are used in the
rhematic disease & related syndromes. Yoshiro Usui & co-workers27 have screened
pyrazoles as fungicidal.
Bruderer-Hans & co-workers28 have synthesised pyrazole & reported their
tranquilizing activity. M. M. El-Kerdawy & co-workers29 have prepared pyrazoles
as herbicidal.
N
N
CF3
NH
NH
O
N
WO - 200380578
Vanilloid Receptor (VR1)
modulators
NN
CH3
Ar
O
OH
CH3
CH3
CH3
WO - 09604273
Anqiotension II (AT-1)
antagonists
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Young Choon Moon30 has reported pyrazole derivatives (II) as protein
kinase inibitors. El-Emery et. al.31 have synthesised 1,3-diphenyl pyrazole
derivatives (III) and reported their variety of biological activities.
Feid-Allah Hassan32 have prepared pyrazoles and reported their antidiabetic
and antibacterial activity. Ejima Akio et. al.33 have synthesised pyrazole
derivatives as antitumor agent (IV). Recently, Atkinson R. N. et. al.34 have
synthesised pyrazoles as sodium channel blocker (V). Murakani Hirani et. al.35
have synthesised pyrazole as antifoulling agent.
Graid Mamalo et. al.36 have newly synthesised pyrazole derivatives tested
for antimicrobial activity. Carbau Rouald and co-worker37 have prepared pyrazole
derivatives (VI) useful as reverse transcriptase inhibitors for the treatment of HIV
infection. Giuseppe Daidone et. al. have studied pyrazole derivative with
hydrazide as side of type (VII) used as to inhibit fibrosis and to treat fibrosis
disorder38,39.
N N
Ph
Ph
CHO
(III)
N
N
N
N
N
Me
MeS
NH
OCH2Ph
(II)
N
Cl
N
N CH3
N N
Cl
F
(IV) (V)
N
N
CF3
CO
NH N
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Laborde Edgardo et. al.402 have found that pyrazole possess glycine
transport-2-inhibitors activity. Andrew-Thurkaub et. al.41 have synthesised high
affinity C5a receptor modulator pyrazoles. Nagaaki Sato et. al.42 have prepared
pyrazole as neuropeptide T5 receptor antagonists. G. Yamanouch Pharma. Co43
has suggested pyrazoles as glycine transporter protein inhibitors (VIII).
Ohki H. et. al.44 have synthesised novel pyrimidinyl pyrazole derivatives
possessing antiproliferature activity. Jun Sun et. al.45 have studied pyrazole
derivative of type (IX) used as antagonists for Estrogen receptor - α.
Cl
Cl S
N
N
Me
Me
OH
NH
NN
R
O
NH
NH2
O
R1
(VI) (VII) R, R' = Alkyl/Aryl
(VIII)
N
N
N
H
F
O
O
C2H5
NN
X
OH
OH
RO
(IX)
X = Alkyl
R = Aryl/Alkyl
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Recently, some pyrazole derivatives (X) have been synthesised as a potential
PET ligand for CB1 receptors by J. S. Dileep et. al.46
Gabriele Murineddu et. al.47 have reported pyrazole derivatives (XI) as
cannabinoid CB1 & CB2 receptor. Recently S. Prasanna & co-workers
48 have
found pyrazole (XII) as COX-2 inhibitors.
Pyrazole(XIII) has found as potential glucocorticoid receptor ligand for
position emission tomography (PET) by Frank Wiist et. al.49. Toshio Nakaura et.
al.50 have discovered pyrazole (XIV) as potent inhibitory activity toward 20-HETE
synthase.
N N
H3CO
CH3
Cl
CO
NH
N
N
N
O
NH
Q
R
R1
(XI)
R,R' = Alkyl
Q = Heteroaryl
NN
A
B
CH3
CH3
(XI)
A,B = hetero atom
(X)
N
N
F
CH3
OH
OH
OH
O
18 F
(XIII)
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Zhaozhony J. Jia et. al.51 have synthesised pyrazoles (XV) as potent and
selective factor Xa inhiitors with desired in vitro anticoagulant activity.
Looking to the diversified biological activity, it appeared of interest to
synthesise some chalcones, pyrazolines, cyanopyridines, thiazolidinones,
pyrimidinones, isoxazoles, cyanopyridones, nitriles bearing pyrazole moiety, in
order to achieving compounds having better therapeutic importance. These study
are described in the following parts.
[A] STUDIES ON PYRAZOLES
PART - I : STUDIES ON PYRAZOLYLPYRAZOLINES
PART - II : STUDIES ON CYANOPYRIDINES
PART - III : STUDIES ON THIAZOLIDINONES
PART - IV : STUDIES ON PYRIMIDINONES
PART - V : STUDIES ON ISOXAZOLES
PART - VI : STUDIES ON CYANOPYRIDONES
PART - VII : STUDIES ON IMIDAZOLINONES
PART - VIII : STUDIES ON NITRILES
N
N
O
NH NO
CH3
(XIV)
(XV)
N N
O
NH
CH3
Z
NR
N
R2
R1
Z = F & SO2Me
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  PART-I
  STUDIES ON
             PYRAZOLINES
INTRODUCTION
Amongst nitrogen containing five membered heterocycles, pyrazolines have
been proved to be the most useful skeleton for biological activities. Pyrazolines
have attracted attention of medicinal chemists for both with regard to heterocyclic
chemisry and the pharmacological activities associated with them. In 1967 Jakobe,
reviewed the chemistry of pyrazolines, which have been studied extensively for
their biodynamic behaviour52 and industrial applications53.
SYNTHETIC ASPECTS
Different methods for the preparat ion of 2-pyrazol ine derivat ives
documented in literature are as follows.
1. 2-Pyrazolines can be constructed by the cyclocondensation of chalcones
with hydrazine hydrate54.
2. 2-Pyrazoline can also be prepared by the conjugate addition of hydrazines
to α,β-unsaturated nitrile followed by cyclisation55.
N
H
N
N
H
NR
R1
R
O
R1
+ NH2.NH2.H2O
R
N + R1.NH.NH2
NaOEt, EtOH
Reflux
N
N
NH2
R
R1
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3. 2-Pyrazoline can be prepared by the condensation of α,β-unsaturated ketone
and thiosemicarbazide in presence of basic alumina & K2CO3.
56
4. Dipolar cycloaddition of nitriles of dimethyl fumarate, fumaronitrile and the
N-aryl maleimides yields the corresponding pyrazolines57.
5. Epoxidation of chalcones have epoxy ketones which reacted with hydrazine
and phenyl hydrazine to give pyrazolines58.
MECHANISM
The following mechanism seems to be operable for the condensation of
chalcones with hydrazine hydrate59.
Nucleophillic attack by hydrazine at the β-position of the α,β-unsaturated
carbonyl system forms species (II), in which the -ve charge is mainly accomodated
by the electronegative oxygen atom.
::
R1R
O
NH2-NH
O-
C+
CH- RR1
NH
R2 NH2
( i ) proton transfer
( ii ) ketonisation
O
RR1
N
NH2R2
nucleophillic attack
intermolecular
N N
H
OH
RR1
R2
-H2O
N N
RR1
R2
R2
(II)(I) (III)
(IV)(V)
R
O R'
+ NH2
S
NH NH2
Basic alumina/K2CO3 N
N
R
R'
S
NH2
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Proton transfer from the nitrogen to -ve oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intermolecular
nucleophillic attack by the primary amino group to ketoamine on its carbonyl
carbon followed by proton transfer from nitrogen to oxygen leads ultimately  to
carbonyl amine (IV). The later with a hydroxy group and amino group on the
same carbon lose water molecule to yield the pyrazolines (V).
THERAPEUTIC IMPORTANT
From the literature survey, it was revealed that 2-pyrazoline derivatives shows
following activities.
1. Analgesic60
2. Bactericidal61
3. Cardiovascular62
4. Diuretic63
5. Fungicidal64
6. Hypoglycemic65
7. Herbicidal66
8. Insecticidal67
9. Tranquilizing68
10. Antiallergic69
11. Anticonvulsant70
12. Antidiabetic71
13. Antiimplantation72
14. Antiinflammatory73
15. Antitumor74
16. Antineoplastic75
Ekta Bansal and co-workers76 have synthesised 1-acetyl-5-substituted ary-
3-(b-aminoaphthyl)-2-pyrazolines which acts as antiinflamnmatory agent. F.
Chimenti et. al.77 have discovered series of N.1-substituted 3-5-diphenyl
pyrazolines (I) and reported their antiHelicobacter pyroli activity.
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Nugent Richard78 investigated pyrazoines bis phosphanate ester as novel
antiinflammatory and antiarthritic agents. Furthermore, Tsuboi et. al.79 have
synthesised some new (phenylcarbonyl) pyrazoline (II) as an insecticides and at
40% concentration show 100% mortality of spodopetra litura larve after seven
drops.
Gulhan Taran-Zitouni et. al.80 have demonstrated 1-(4-arylthiazol-2-yl)-3,5-
diaryl-2-pyrazolines (III) as antihypertensive agents. S. P. Hiremath et. al.81 have
reported substituted pyrazolines as analgesic, antiinflammatory and antimicrobial
agents. Malhotra et. al.82 have prepared 1-thiocarbamoyl-2-pyrazolines
derivatives (IV) as anticardiovascular agents.
NN R''
R
R'
R, R' = Alkyl
R'' = Alkyl / Aryl(I)
N
N
O
NH
CF3
R (II) R = Aryl
N
N
R2
S
N
R3
R1
(III)
N
N
R1
S
NH
R2
(IV)
R1,R2,R3 = Aryl R1,R2 = Aryl
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Nesr in  Gokhan e t .  a l .83 have synthes i sed new 1,N-subs t i tu ted
thiocarbomoyl-3-phenyl-5-thienyl-2-pyrazoline derivatives and evaluated theirs
for antidepressant, antiogenic and mammalianmonoamine oxidase (MAO)- A &
B inhibitory activities. jin Hee Ahn et. al.84 have synthesised new series of cyano
pyrazoline derivatives (V) through achiral and chiral synthetic methods and
evaluated for their ability to inhibite dipeptidyl peptidase IV (DP-IV) as potent
antidiabetic agents.
Maria Celoni et. al.85 have discovered some new pyrazoline derivatives and
reported as α2-adrenoceptors and 5-HT receptors mediate, the antinociceptive
effect. Novel 3,5-diaryl pyrazolines (VI) have been discovered as low density
lipoprotein (LDL) oxidation inhibitor by Tae-Sock  et. al.86
Adnan and Tarek87 have synthesised pyrazoline derivatives (VII) as
antiinflammatory antimicrobial agents.
N
N
NH
NH
O
N
N
CN
(V)
NHN R1
R2
OH
R3
t-Bu
OH
t-Bu
(VI)
R1,R2,R3 = Alkyl
N
N
S
N N
Br
R
CH3
(VII) R = Alkyl / Aryl
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A ser ies  o f  new 1,N-subs t i tu ted pyrazo l ine  ana logues  (VI I I )  o f
thiosemicarbazones were synthesised by Mohammad Abid and Amir Azam88 as
antiamoebic agent. Abbas Sdhafiee et. al.89 have demonstrated 1-(4-aryl-2-
thiazolyl)-3,5-disubstituted-2-pyrazolines (IX) which acts as antinociceptive
agents.
CONTRIBUTION FROM OUR LABORATORY
Parekh et. al.90 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-
4-one-3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Tejas Upadhyay et. al.91 and sohit Rajvaidya et. al.92 have prepared pyrzolines
as antimicrobial agent.
A. V. Dobaria & Co-workers93 has discoverd pyrazol ines bearing
chloroquinoline nucleus which used as antimicrobial agents. Jatin Upadhyay
et. al.94 have described pyrazoline derivatives as antimicrobial agents. Akhil Bhatt
and co-workers95 have reported pyrazoline derivatives showing antimicrobial
activity.
N
H
N
Cl
S
N
CH3
CH3
(VIII)
S
N
NN
N
R3
R4
R2
R1
(IX)
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With an aim to synthesise better therapeutic agents, we have investigated
some new pyrazolines to enhance the overall drug potential of resulting
compounds which have been described as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1-ARYL-3-[1 ' -N-PHENYL-3 ' -p-FLUOROPHENYL
PYRAZOL-4'-YL]-2PROPENE-1-ONES
SECTION - II: SYNTHESIS AND THERAPEUTIC EVALUATION OF
3-ARYL-5-[1 ' -N-PHENYL-3 ' -p-FLUOROPHENYL
PYRAZOL-4'-YL]-PYRAZOLINES
SECTION - III : SYNTHESIS AND THERAPEUTIC EVALUATION OF
1 , N -P H E N Y L - 3 -A RY L - 5 - [ 1 ' N , -P H E N Y L - 3 ' - p -
FLUOROPHENYL PYRAZOL-4'-YL]-PYRAZOLINES
N
N
N
R
Cl
(X)
R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1'-N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-2-PROPENE-1-ONES
Recently, much interest has been focused on the synthesis and biodynamic
activities of chalcones and it is a good synthon for verious heterocyclic rings.
With a view to obtainng compounds having better therapeutic activity, we have
synthesised 1-aryl-3-(1',N-phenyl-3'-p-flurophenyl-pyrazol-4'-yl)-2-propene-1-
ones by the condensation of 1-phenyl-3-p-fluorophenyl-4-formyl-pyrazole with
various aromatic ketones in alkaline solution.
The constitution of the synthesised compounds have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N
N
O
R
FN
N
CHO
F
R CH3
O
40% KOH
R = ArylType - (I)
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REACTION SCHEME
Type - (I) R = Aryl
N
N
O
R
F
N
N
CHO
F
R CH3
O
40% KOH
Vilsmeier-Haack
Formylation
NH
N
F
CH3
Cat. gla. CH3COOH
Abs. C2H5OH
F
CH3
O
NH
NH2
+
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IR SPECTRAL STUDY OF 1-(p-ANISYL)-3-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-2-PROPENE-1-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2933 2975–2950 426
–CH
3
C – H str. (sym.) 2835 2880–2860 "
C – H i.p. (def.) 1450 1470–1435 "
C – H o.o.p. (def.) 1361 1385–1350 "
Aromatic C – H str. 3049 3130–3030 427
C = C str. 1502 1585–1480 "
C – H i.p. (def.) 1064 1125–1090 "
C – H o.o.p. (def.) 833 835-810 "
Pyrazole C = N str. 1606 1650–1580 428
moiety C – N str. 1259 1350–1200 "
C – F 752 760-710 "
Ether C – O – C str. (asym). 1220 1275–1200 "
C – O – C str. (sym). 1029 1075–1020 "
Chalcone C = O str. 1660 1760–1655 429
N
N
O
F
H3CO
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PMR SPECTRAL STUDY OF 1,p-ANISYL-3-[1',N-PHENYL-3'-p-FLOROPHENYL-
PYRAZOL-4'-YL]-PROPENE-1-ONE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.89 1H singlet Ar-OCH
3
-
2. 6.95-6.98 2H doublet Ar-Hgg' Jgf=8.7
3. 7.16-7.22 2H triplet Ar-Hdd' -
4. 7.33-7.40 2H quartet -CH(h&i) -
5. 7.48-7.53 2H triplet Ar-Hee' -
6. 7.67-7.72 2H multiplet Ar-Hbb' -
7. 7.98-7.81 3H triplet Ar-Hcc'+Ha -
8. 7.96-7.99 2H doublet Ar-Hff' Jfg=8.7
9. 8.34 1H singlet CHx -
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EXPANDED AROMATIC REGION
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ANTIMICROBIAL ACTIVITY
Method : Cup-Plate96
Gran positive bacteria : B. cocous and B. subtillus
Gram negative bacteria : Proteus vulgaris
Escherichia coli
Fungi : Aspergillus niger
Concentration : 40 µg
Solvent : Dimethyl formamide
Standard drug : Amoxycillin, Benzoylpenicillin,
Ciprofloxacin, Erythromycin, Greseofulvin.
The antimicrobial act ivi ty was compared with standard drugs viz.
Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin, and antifungal
activity was compared with viz Greseofulvin. The zone of inhibition measured in
mm.
ANTITUBERCULAR ACTIVITY
The antitubercular activity was carried out at Tubrerculosis Antimicrobial
Acquisition and Co-ordinating Facility (TAACF) U.S.A.
Method : BACTEC 460 Radiometric system.
Bacteria : Mycobacterium tuberculosis H37Rv
Concentrtion : 6.25 µg/ml.
Standard drug : Rifampin
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENE-1-ONES
[A] Synthesis of N-Aminophenyl-α-methyl-p-flurophenyl azomethine
A mixture of phenylhydrazine (1.08 g, 0.01M) and p-flurophenyl aceto
phenone (1.38 g, 0.01M) in absolute ethanol was refluxed in water bath for 2
hrs. in presence of 1 ml glacial acetic acid. The crude product was isolated and
crystallised from absolute alcohol. yield. 90%, m.p. 38oC; (C14H13FN2 ; Found :
C, 72.63%, H, 5.70%; N, 12.21%; Required : C, 73.66%; H, 5.74%; N, 12.27%)
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
N-Aminophenyl-α-methyl-p-fluorophenyl azomethine (2.27g, 0.01M) was
added in mixture of Vilsmeir-Haack reagent (prepared by dropwise addition of 3
ml POCl3 in ice cooled 25 ml DMF). and refluxed for 5 hrs. The reaction mixture
was poured into ice followed by neutralization using sodium bicarbonate. Crude
product was isolated and crystallised from ethanol yield 75%, m.p. 155oC;
(C16H11FN2O ; Found C, 72.11%; H, 4.12%; N, 10.48%; Required ; C, 72.11%;
H, 4.16%; N, 10.52%).
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-fluorophenyl pyrazol-
4'-yl)-2-propene-1-one
To a well stirred solution of 1,N-phenyl-3-p-fluorophenyl-4-formyl-pyrazole
(2.65gm, 0.01M) and p-methoxy-acetophenone (1.5 g, 0.01M) in ethanol (25
ml), 40% KOH added till the solution become basic. The reaction mixture was
stirred for 24 hrs. The contents were poured into ice, acidified, filtered and
crystallised from ethanol. Yield,78%, m.p.180oC. (C25H19FN2O2 ; Found :
C,75.33%; H, 4.77%; N, 6.94%; Requires : C, 75.36%; H, 4.81%; N, 7.03%).
Similarly, other substituted chalcones have prepared. The physical data are
recorded in Table No. 1.
[D] Antimicrobial activity of 1-Aryl-3-[1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl]-2-propene-1-ones
All the products have been evaluated by antimicrobial activity as described
under.
(a) Antimicrobial activity
It was carried out by cup-plate diffusion method which has been described
as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The
nutrient agar broth prepared by the usual method was inoculated aseptically with
0.5 ml of 24 hrs. old subcultures of B. cocous, B. subtillus, E. coli, P.
vulgaris in separate conical flasks at 40-50oC and mixed well by gentle shaking.
About 25 ml content of the flast were poured and evenly spread in a pertidish
(13 cm in diameter) and allowed to set for 2 hrs. The cup (10 mm in diameter)
were formed by the help of borar in agar medium and filled with 0.04 ml (40 µg)
solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also
maintained with 0.04 ml of DMF in a similar manner and the zones of inhibition
of the bacterial growth were measured in millimeter and are recorded in graphical
chart no.1.
(II) Antifungal activity
A. Niger was employed for testing antifungal activity using cup-plate
method. The culture was maintained on Sabouraud's agar slants. Sterilised
Sabouraud's agar medium was inoculated with 72 hrs. old 0.5 ml of suspension
of fungal spores in a separate flask. About 25 ml of the inculated medium was
evenly spreaded in a petridish and allowed to set for two hrs. The cups (10 mm
36
in diameter) were punched. The plates were incubated at 30oC for 48 hrs. After
the completion of incubation period, the zones of inhibition of growth in the
form of diameter in mm was measured Along the test solution, in each petridish
one cup was filled up with solvent which acts as control. The zones of inhibition
are recorded in graphical chart no.1.
(b) Antitubercular Activity
The antitubercular evaluation of the compounds was carried out at
Tuberculosis Antimicrobial Acquisition and Co-ordinating Facility (TAACF),
U.S.A. Primary screening of the compounds for antitubercular activity have been
conducted at 6.25 µg/ml towards Mycobacterium Tuberculosis H37Rv in
BACTEC 12B medium using the BACTEC 460 radiometric system. The
compounds demonstrating atleast > 90%. inhibition in the primary screen have
been retested at lower concentration towards Mycobacterium Tuberculosis
H37Rv  to determine the actual minimum inhibitory concentration (MIC) in the
BACTEC 460.
The antitubercular activity data have been compared with standard drug
Rifampin at 0.25 µg/ml concentration and it showed 98% inhibition. The work is
under progress.
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TABLE NO. 1 : PHYSICAL CONSTANTS OF 1-ARYL-3-(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-
2-PROPENE-1-ONES
Sr.
No.
1
1a C6H5- C24H17FN2O 368 140 0.41 81 7.60 7.53
1b 4-OCH3-C6H4- C25H19FN2O2 398 180 0.59 78 7.03 6.94
1c 4-CH3-C6H4- C25H19FN2O 382 193 0.47 70 7.33 7.26
1d 4-Cl-C6H4- C24H16ClFN2O 402 210 0.52 73 6.95 6.87
1e 4-F-C6H4- C24H16F2N2O 386 189 0.61 86 7.25 7.16
1f 4-OH-C6H4- C24H11FN2O2 384 240 0.73 84 7.29 7.22
1g 2-OH-C6H4- C24H17FN2O2 384 178 0.44 74 7.29 7.20
1h 4-NO2-C6H4- C24H16FN3O3 413 191 0.56 82 10.16 10.09
1i 3-NO2-C6H4- C24H16FN3O3 413 188 0.64 72 10.16 10.10
1j 4-Br-C6H4- C24H16BrFN2O 447 218 0.57 77 6.26 6.21
1k 4-NH4-C6H4 C24H18FN2O 383 206 0.71 79 10.96 10.88
1l C4H3S- C22H15FSN2O 374 174 0.58 76 7.48 7.42
*TLC Solvent System : Acetone : Benzene
2 : 8 (1a-1e, 1g-1j, 1l)
3 : 7 (1f, 1k)
Rf*
Value
6
Yield
%
7
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3
38
39
N
N
O
F
O CH3
N
N
O
F
291
N
N
CH2
F
F
N
N
N
N
O
F
O
CH3
107
NH
N
CH2
F
399(m+1)
189(m+1)
N
N
O
F
CH3
307 (m+1)
323 (m+1)
369(m +1)
238
263
N
H
N
O
O
CH3
F
CH3
O
O
CH3
165 (m+1)
+
+
+
+ +
+
+
+
+
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
m/z
+
GRAPHYCAL CHART NO.1:    ANTIMICROBIAL  ACTIVITY OF 1-ARYL-3-[1’N-PHENYL-3’-p-FLOROPHENYL PYRAZOL-4’-YL]-2-
                                                     PROPENE-1-ONES.
0
10
20
30
Zo
ne
 
o
f i
n
hi
bi
tio
n
 in
 
m
m
B. cocous 19 18 9 8 11 10 13 14 16 18 17 11 17 21 16 23 0
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of chalcones (type-I) revealed that all the
compounds were able to inhibit the growth of Gram positive & Gram negative
bacterial strains.
Maximum activity was observed in compounds bearing R = phenyl and 4-
fluorophenyl which was compared to standard drugs against Gram positive
bacterial  strains B. cocous & B. subtillus. Significant activity was displayed
by compounds bearing R=4-methylphenyl, 4-nitrophenyl, 4-bromophenyl,
thiopene except 4-chlorophenyl.
In case of Gram negative bacterial species, maximum activity was observed
in compound bearing R=2-hydroxyphenyl and 3-nitrophenyl against Gram
negative bacterial species P. vulgaris & E. coli singificant activity was displayed
by compound bearing R=phenyl ,  4-methoxyphenyl ,  4-ni t rophenyl ,  4-
bromophenyl and 4-hydroxyphenyl.
ANTIFUNGAL ACTIVITY
Most of the compound were mild to moderately active against fungal strain
A. niger. Maximum activity was observed in compound bearing R=4-nitrophenyl
which was compared to standard drug.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1'-N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-PYRAZOLINES
Looking at versatile therapeutic importance and with an aim to getting better
drug, it was considered worthwhile to synthesise some new pyrazolines. The
preparation of 3-aryl-5-(1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl)-pyrazolines
(II) has been undertaken by cyclocondensation of chalcones of type (I) with
hydrazine hydrate.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
N
N
F
N
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R
N
N
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F
NH2.NH2.H2O
R = ArylType - (II)
42
IR SPECTRAL STUDY OF 3-(p-ANISYL)-5-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2918 2975–2920 426
–CH
3
C – H str. (sym.) 2839 2880–2820 "
C – H i.p. (def.) 1448 1470–1435 "
C – H o.o.p. (def.) 1348 1385–1350 "
Aromatic C – H str. 3072 3080–3030 427
C – H i.p. (def.) 1157 1160–1090 "
1033 1070-1000 "
C – H o.o.p (def.) 835 835–810 "
Pyrazole C = N str. 1602 1650–1600 428
moiety C = C str. 1512 1585–1480 "
C – N str. 1317 1350–1200 "
C – F str. 756 760–710 "
Ether C – O – C (asym.) 1255 1275–1200 "
C – O – C (sym.) 1074 1075–1020 "
Pyrazoline C = N str. 1550 1627–1550 429
N – H str. 3317 3450–3250 "
N
N F
N
NH
OCH3
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PMR SPECTRAL STUDY OF 3-(p-ANISYL)-5-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.00-3.08 1H d. doublet CHh Jhi =
Jhj =
2. 3.35-3.48 1H d. doublet CHi Jih =
Jij =
3. 3.83 3H singlet Ar-OCH
3
-
4. 5.05-5.22 1H d. doublet CHj Jih =
Jji =
5. 6.88-6.92 2H doublet Ar-Hgg' Jgf=8.7
6. 7.10-7.21 2H triplet Ar-Hdd' -
7. 7.25-7.30 2H triplet Ar-Hbb' -
8. 7.35-7.46 2H triplet Ar-Hcc' -
9. 7.60-7.62 2H doublet Ar-Hee' Jed=8.7
10. 7.67-7.72 3H triplet Ar-Hff'+Ha Jfg=8.4
11. 8.04 1H singlet CHx -
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EXPANDED AROMATIC REGION
N
N
F
N
NH
OCH3
b
c
c'
b'
x
d e
e'd'
h
i
f'
f
g
g'
a
j
N
N F
N
NH
OCH3
m/z = 412 (m)
EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N-Aminophenyl-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-fluorophenyl-pyrazol-
4'-yl)-2-propene-1-one
See Part-I, Section-I (C).
[D] Synthesis of 3-(p-Anisyl)-5-(1'-N-phenyl-3'-p-fluorophenyl-pyrazol-
4'-yl)-pyrazoline
A mixture of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-flurophenyl-pyrazol-4'-yl)-2-
propene-1-one (3.98 g, 0.01M) in 25 ml of absolute alcohol, add hydrazine
hydrate (0.5g, 0.01M) was refluxed in water bath at temp. 80-90oC for 8 hrs. The
reaction mixture was poured into ice. The product was isolated and crystallised
from ethanol, yield 59%, m.p. 140oC; (C25H21FN4O ; Found : C, 7272%; H,
5.09%; N, 13.52% ; Requires : C, 72.80%; H, 5.13%; N, 13.58%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 2.
[E] Antimicrobial activity of 3-Aryl-5-(1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl-)pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.2.
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TABLE NO. 2 : PHYSICAL CONSTANTS OF 3-ARYL-5-(1',N-PHENYL-3'-p-FLUOROPHENYL-PYRAZOL-4'-YL)-
PYRAZOLINES
Sr.
No.
1
2a C6H5- C24H19FN4 382 246 0.51 61 14.65 14.61
2b 4-OCH3-C6H4- C25H21FN4O 412 140 0.38 59 13.58 13.52
2c 4-CH3-C6H4- C25H21FN4 396 164 0.43 65 14.13 14.08
2d 4-Cl-C6H4- C24H18ClFN4 416 142 0.44 66 13.44 13.39
2e 4-F-C6H4- C24H18F2N4 400 146 0.60 63 13.99 13.91
2f 4-OH-C6H4- C24H19FN4O 398 150 0.54 70 14.06 14.00
2g 2-OH-C6H4- C24H19FN4O 398 255 0.67 62 14.06 13.98
2h 4-NO2-C6H4- C24H18FN5O2 427 275 0.75 65 16.38 16.31
2i 3-NO2-C6H4- C24H18FN5O2 427 128 0.36 71 16.38 16.32
2j 4-Br-C6H4- C24H18BrFN4 461 160 0.49 64 12.14 12.07
2k 4-NH2-C6H4 C24H20FN5 397 157 0.39 68 17.62 17.56
2l C4H3S- C22H17FSN4 388 184 0.52 67 14.42 14.37
*TLC Solvent System : Ethyl acetate : Hexane
2 : 8 (3a-3f, 3i-3l)
2.5 : 7.5 (3g, 3h)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
47
48
N
N
F
NH
N
OCH 3
2 64
N
N
CH2
F
NH2279
N
N
F
239 (m + 1)
NH
N
H
F
165 (m + 1)
N
N
H
NH2175
OCH 3
107
N
N
F
NH
N
307 (m + 1)
N
N
F
NH
N
38 3 (m + 1 )
NH
N
OCH 3
175 (m + 1)
NH
N
F
NH
N
232 (m + 2)
m/z
m/z
m/z
m/z
m/z
m/z
N
N
CH2
F
m/z
m/z
m/z
m/z
+
+
+
+
+
+
+
+
+
+
m/z
+
41 2 (m )
GRAPHYCAL CHART NO.2: ANTIMICROBIAL ACTIVITY OF 3-ARYL-5-[1’N-PHENYL-3’-p-FLUOROPHENYL PYRAZOL-4’-YL]-PYRAZOLINES.
0
10
20
30
Zo
ne
 
o
f i
n
hi
bi
tio
n
 in
 
m
m
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B. subtillus 15 17 11 10 8 13 17 13 16 18 10 11 15 21 22 19 0
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P. vulgaris 10 14 15 17 19 16 14 13 11 17 16 14 16 19 15 21 0
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been concluded from the experimental data that pyrazoline derivatives
(type-II) were able to inhibit the growth of Gram positive and Gram negative
bacterial strains.
Maximum activity was observed in compounds bearing R=4-bromophenyl
& phenyl against Gram positive bacterial strains B. cocous & B. subtillus.
Significant activity was observed in compounds bearing R=4-methoxyphenyl,
4-aminophenyl against Gram positive bacterial strains B. cocous & B. subtillus.
While in case of Gram negative bacterial stains, maximum activity was
observed in compound bearing R=4-fluorophenyl & 3-nitrophenyl & significant
activity was observed in compound bearing R=4-bromophenyl & 4-aminophenyl
against P. vulgaris & E. coli. Other compounds were mild to moderately active.
ANTIFUNGAL ACTIVITY
All the compound were mild to moderately active against fungal strain
A. niger with comparable to standard drugs, while maximum activity was
observed in compound bearing R=4-hydroxyphenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
50
SECTION - III
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5-(1 ' ,N-PHENYL-3 ' -p-FLUOROPHENYL PYRAZOL-4 ' -YL)-
PYRAZOLINES
Looking to the interesting therapeutic activities of pyrazolines, it was
considered worthwhile to synthesise compounds bearing 1-N-phenyl-3-p-
fluorophenyl-4-formyl-pyrazole moiety linked to the pyrazoline of type- (III) which
have been prepared by the action of 1-aryl-3-(1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl)-2-propen-1-ones with phenyl hydrazine in presence of piperidine.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
R = ArylType - (III)
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IR SPECTRAL STUDY OF 1,N-PHENYL-3-(p-ANISYL)-5-(1 ' ,N-PHENYL-3' -p-
FLUOROPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2925 2975–1920 426
–CH
3
C – H str. (sym.) 2837 2880–2850 "
C – H i.p. (def.) 1446 1470–1435 "
C – H o.o.p. (def.) 1375 1385–1350 "
Aromatic C – H str. 3068 3080–3030 427
C – H i.p. (def.) 1110 1125–1090 "
1031 1070–1000 "
C – H o.o.p (def.) 842 845–810 "
Pyrazole C = N str. 1637 1650–1600 428
moiety C = C str. 1506 1585–1480 "
C – N str. 1286 1350–1200 "
C – F str. 756 760–720 "
Ether C – O – C str. (asym.) 1257 1275–1200 "
C – O – C str. (sym.) 1061 1075–1020 "
Pyrazoline C = N str. 1606 1627–1580 429
C – H def. 686 698–680 "
N
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PMR SPECTRAL STUDY OF  1,N-PHENYL-3-(P-ANISYL)-5-[1',N-PHENYL-3'-p-
FLUOROPHENYL-PYRAZOL-4'-YL]-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.16-3.23 1H d. doublet CHh -
2. 3.76-3.82 1H d. doublet CHi -
3. 3.83 3H singlet Ar-OCH3 -
4. 5.39-5.45 1H d. doublet CHj -
5. 6.77-6.82 1H triplet Ar-Ha -
6. 6.89-6.92 2H doublet Ar-Hgg Jgf=6.96
7. 7.06-7.09 2H doublet Ar-Hdd' Jde=8.7
8. 7.16-7.23 5H multiplet Ar-Hbb'+Hii+Hk -
9. 7.35-7.41 2H triplet Ar-Hee' -
10. 7.62-7.70 4H triplet Ar-Hmm'+Hcc' -
11. 7.75-7.83 3H quartet Ar-Hff'+CHx -
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-PHENYL-3-
ARYL-5-(1 ' ,N-PHENYL-3 ' -p-FLUOROPHENYL PYRAZOL-4 ' -YL)-
PYRAZOLINES
[A] Synthesis  o f  N-Aminophenyl - α -methyl - α -p - f luorophenyl -
azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-(1'-N-phenyl-3'-p-fluorophenyl-pyrazol-
4'-yl)-2-propene-1-one
See Part-I, Section-I (C).
[D] Synthesis  of  1,N-Phenyl -3- (p-anisyl ) -5- (1 ' , -N-phenyl -3 ' -p -
fluorophenyl pyrazol-4'-yl)-pyrazoline
To a mixture of 1-(p-Anisyl)-3-(1',N-phenyl)-3'-p-fluorophenyl-pyrazol-4'-
yl)-2-porpene-1-one (3.98g, 0.01M) in 25 ml of absolute alcohol add phenyl
hydrazine (1.08g, 0.01M) was added in presence of basic catalyst like piperidine
and refluxed for 12 hrs. at temp 70oC The reaction product was poured into ice.
The product was isolated and crystallised from ethanol Yield 68%, m.p. 84oC
(C31H25FN4O; Found : C, 76.16%; H, 5.11%; N, 11.42%; Requires : C, 76.21%;
H, 5.16%; N, 11.47%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Table No. 2.
[E] Antimicrobial activity of 1,N-phenyl-3-aryl-5-(1',N-phenyl-3'-p-
fluorophenyl pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.3.
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TABLE NO. 3 : PHYSICAL CONSTANTS OF 1,N-PHENYL-3-ARYL-5-[1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL]-PYRAZOLINES
Sr.
No.
1
3a C6H5- C30H23FN4 458 94 0.62 63 12.12 12.17
3b 4-OCH3-C6H4- C31H25FN4O 488 84 0.53 68 11.47 11.42
3c 4-CH3-C6H4- C31H25FN4 472 88 0.54 66 11.86 11.82
3d 4-Cl-C6H4- C30H22ClFN4 492 98 0.48 70 11.37 11.33
3e 4-F-C6H4- C30H22F2N4 476 76 0.42 63 11.76 11.71
3f 4-OH-C6H4- C30H23FN4O 474 78 0.49 65 11.81 11.75
3g 2-OH-C6H4- C30H23FN4O 474 82 0.74 64 11.81 11.73
3h 4-NO2-C6H4- C30H22FN5O2 503 100 0.65 67 13.91 11.86
3i 3-NO2-C6H4- C30H22FN5O2 503 110 0.45 70 13.91 11.84
3j 4-Br-C6H4- C30H22BrFN4 537 80 0.69 61 10.43 10.36
3k 4-NH2-C6H4 C30H24FN5 473 94 0.44 71 14.79 14.72
3l C4H3S- C28H21FN4S 464 91 0.54 60 12.06 12.01
*TLC Solvent System : Acetone : Benzene
2 : 8
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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P. vulgaris 12 18 16 19 12 10 9 10 21 17 26 28 16 19 15 21 0
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CONCLUSION
ANTIBACTERIAL ACTIVITY
It has been observed from the experimental data that pyrazolines (type-III)
show maximum activity against Gram positive bacterial strains and moderately
active against Gram negative bacterial strain.
It has been observed that compounds bearing R=4-methylphenyl, 3-
nitrophenyl & 2-hydroxyphenyl shows promising activity and compounds bearing
R=4-methoxyphenyl, 4-chlorophenyl, 4-hydroxyphenyl, 4-aminophenyl &
thiophene shows significant activity against Gram positive bacterial strains
B. cocous & B. subtillus.
While in case of Gram negative bacterial strains, compounds were moderately
active. Maximum activity was observed in compounds bearing R=4-nitrophenyl,
3-nitrophenyl & 4-fluorophenyl against Gram negative bacterial strains E. coli
and P. vulgaris.
ANTIFUNGAL ACTIVITY
All the compound were mild to moderately active against fungal strain
A. niger .  Maximum activiy was observed in compound bearing R=4-
bromophenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
PART-II
STUDIES ON
         CYANOPYRIDINES
INTRODUCTION
Pyridine and its derivatives are very important in pharmaceutical, agriculture
and industrial chemistry. Some pyridine system is active in the metabolism in the
body certain nitrogenous plant products also have pyridine class compounds.
They can be parent component of many drugs. Pyridine is also used as a
denaturant for antifreeze mixtures, as a dyeing assistant in textiles and fungicides.
Cyanopyridines,  nicot inoni tr i les ,  nicotanamide and nicot inic acid are
intermediates for the preparation of pharmaceuticals and agrochemicals.
SYNTHETIC ASPECTS
Preparation of 3-cyanopyridines is available in the literature97-101 with
different methods.
1. Samour and co-workers102 have prepared substituted cyanopyridines(I) by
the condensation of chalcones with malononitriles in presence of ammonium
acetate.
2. Feng Shi and co-workers103 have prepared 2-amino-3-cyanopyridine
derivative by the reaction of aromatic aldehyde, ketone, malono nitriles and
ammonium acetate under microwave irradiation without solvent.
3. Dao-Lin & Kimiaki104 have prepared 2-methoxy-3-cyano pyridine
derivatives by the condensation of chalcones with malanonitrile in sodium
methoxide.
(I)
R'
O
R
CH2(CN)2
N
R'
N
NH2
R
CH3COONH4
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MECHANISM
The reaction proceeds through conjugated addition of active methylene
compounds to the α,β-unsaturated system as shown below105.
THERAPEUTIC IMPORTANCE
The extensive use of cyanopyridine derivatives have been established in
medicine due to its variety of therapeutic activity shown as under.
1. Analgesic106
2. Insecticidal107
N R'
R
NH2
N
NaOMe
N
N
+
R
O
R'
R, R' = Aryl
R
O
CH3
NH4OAc
R
NH
CH3 R
NH2
CH2
..
Ar CHO +
N
N
-H2O
NH4OAc Ar
N
N
NHR
H
H Ar N
N
NH2R
H
H Ar N
N
..
N
H
R
H
H Ar
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NH NR
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N
NH2
-H2
N NH2
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R
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3. Antisoriasis108
4. Antihypertensive109
5. Antifungal110
6. Antiepileptic111
7. Antibacterial112
8. Anticonvulsant113
F. Manna et. al.114 have prepared 3-cyano-pyridine derivatives as
antiinflammatory, analgesic and antipyretic agents. Aivars Krauze et. al.115 have
synthesised 3-cyanopyridine derivatives & shown their neurotropic activity. Fatma
Goda & co-workers116 have synthesised 2-alkoxy pyridines (II) and studied their
antimicrobial activity.
H. Yoshida et. al.117 have studied the antihistamic & antiallergic activity of
3-cyanopyridine derivatives. Gadaginamath and co-workers118 have synthesised
various cyanopyridyl derivatives (III) and documented their variety of biological
activities.
N
N
CH3
Ar
Ar
(II)
NNNH2
N
H3CO
R
CH3
CH3
O
(III)
R = Aryl
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Hammana Abou and co-workers119 have studied the anticancer and anti-
HIV activity of 3-cyanopyridines. Abdallah Navine et. al.120 have prepared
cyanopyridine derivatives which showed analgesic and antiinflammatory activity.
Abu and co-workers121 have described novel fused cyanopyridines (IV) for
the treatment and preparation of systemic fungal infection.
S. V. Roman et. al.122 have investigated 2-amino-3-cyanopyridine
derivatives and reported their biological activity. El-Taweel and co-workers123
have described cyanopyridine derivatives (V) and showed their significant
biological activity.
Francis and co-workers124 have studied the effect of some substituted
pyridines on the growth of the walker carcinosarcome-256 in tissue culture. H.
W. Hoefling and co-workers125 have documented 3- and 4-cyanopyridines as
tuberculosis arresting agents.
Hironori et. al.126 have prepared cyanopyridines and screened for their large
conductance calcium activiated potassium channel opener activity. Pyachenko
V. D. and co-workers127 have shown some cyanopyridines (VI) which are useful
in treatment of retroviral disease.
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(IV)
N S
N
NH2
N
NH2
N
CH3
N
O
NH2NC
(V)
CONTRIBUTION FROM OUR LABORATORY
Akhil Bhatt and co-workers128 have synthesised cyanopyridines as potential
antimicrobial agents. R. C. Khunt et. al.129 have screened cyanopyridine
derivatives used as biologically active agents. Synthesis and antimicrobial activity
of cyanopyridines is shown by B. P. Kansagara et. al.130 J. R. Patel & co-
workers131 have prepared cyanopyridines bearing 2-chloro-6-bromoquinoline
nucleus as potential anticancer agents.
Synthesis and biological evaluation of cyanopyridines is screened by Pankaj
Patel & co-workers132. Rajeev Doshi and co-workers133 have described some
novel cyanopyridines as a new class of potential antitubercular agents.
Cyanopyridines have been screened by A. V. Dobaria et. al.134 and showed their
significant biological activity. Ketan Hirpara & co-workers135 have discovered
cyanopyridines as antitubercular agents (VII).
N
N
N
NH2
Se
(VI)
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N
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N
NH2
N
R
(VII)
Thus, diverse biological activities have been encountered in compounds
containing cyanopyridine ring system. To further assess the potential of such a
type of compounds, study of cyanopyridines have been carried out as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
A M I N O - 3 - C YA N O - 4 - [ 1 , ' N - P H E N Y L - 3 ' - p -
FLUOROPHENYL PYRAZOL-4 ' -YL] -6-ARYL-
PYRIDINES
SECTION - II: SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
A M I N O - 3 - C YA N O - 4 - [ 1 , ' N - P H E N Y L - 3 ' - p -
FLUOROPHENYL PYRAZOL-4 ' -YL] -6-ARYL-
PYRIDINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-
4-[1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'YL]-6-ARYL-
PYRIDINES
In the past years, considerable evidence has been accumulated to
demonstrate the efficiency of cyanopyridines. To further assess the potential of
such a class of compounds cyanopyridine derivatives of type (IV) have been
synthesised by condensation of malononitrile and ammonium acetate with 1-
aryl-3-[1',N-phenyl-3'-p-flourophenyl pyrazole-4'-yl]-2-propene-1-ones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activity of synthesised compounds were compared with standard
drugs.
R = ArylType - (IV)
N
N
O
R
F
CH2.(CN)2
N
N
F
N
R
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CH3COONH4
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IR SPECTRAL STUDY OF 2-AMINO-3-CYANO-4-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-6-(p-ANISYL) PYRIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2987 2995–2920 429
–CH
3
C – H str. (sym.) 2852 2880–2850 "
C – H i.p. (def.) 1454 1470–1435 "
C – H o.o.p. (def.) 1338 1385–1330 "
Aromatic C – H str. 3066 3080–3010 427
C – H i.p. (def.) 1026 1110–1000 "
C – H o.o.p (def.) 839 835–810 "
Pyrazole C = N str. 1602 1650–1600 428
moiety C = C str. 1546 1585–1480 "
C – N str. 1222 1350–1200 "
C – F str. 758 760–710 "
Ether C – O – C str. (asym.) 1251 1275–1200 "
C – O – C str. (sym.) 1064 1075–1020 "
Pyridine C ≡ N str. 2187 2240–2120 429
ring C = N str. 1579 1650–1600 "
N – H str. (–NH
2
) 3355 3400–3250 "
N
N F
N
NH2
N
OCH3
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PMR SPECTRAL STUDY OF  2-AMINO-3-CYANO-4-[1',N-PHENYL-3'-p-FLUORO
PHENYL PYRAZOL-4'-YL]-6-(p-ANISYL)-PYRIDINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.84 3H singlet Ar-OCH
3
-
2. 5.28 2H singlet -NH
2
-
3. 6.90-6.93 3H triplet Ar-Hgg' + Hh Jgf=8.7
4. 7.06-7.12 2H triplet Ar-Hdd' -
5. 7.33-7.38 1H triplet Ar-Ha -
6. 7.48-7.53 2H triplet Ar-Hbb' -
7. 7.56-7.61 2H multiplet Ar-Hcc' -
8. 7.70-7.74 2H doublet Ar-Hee' Jed=8.7
9. 7.78-7.81 2H doublet Ar-Hff' Jfg=8.1
10. 8.37 1H singlet CHx -
N
N F
N
NH2
N
OCH3
b
c
c'
b'
x
d e
e'd'
a
f'
f g
g'
h
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-3-CYANO-
4-[1' ,N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-6-ARYL
PYRIDINES
[A] Synthesis of N-Aminophenyl-α-methyl-p-fluorophenyl azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-phenyl-3-(1'-N-phenyl-3'-p-fluorophenyl pyrazol-4'-
yl)-2-propene-1-one
See Part-I, Section-I (C).
[D] Synthesis of 2-Amino-3-cyano-4-[1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl]-6-(p-anisyl)-pyridine
A mixture of 1-Anisyl-3-(1',N-phenyl)-3'-p-fluorophenyl-pyrazol-4'-yl)-2-
porpene-1-one (3.98 g, 0.01M), malononitrile (0.66 g, 0.01 M) and ammonium
acetate (6.61g, 0.08M) dissolved in absoulte alcohol was refluxed for 10 hrs. at
to mp 60-70oC  The reaction product was poured into ice, crude product was
isolated, crystallised from ethanol. Yield 65%, m.p. 234oC (C28H20FN5O ; Found
: C, 72.72%; H, 4.30%; N, 15.11%; Requires : C, 72.81%; H, 4.37%; N, 15.18%).
Similarly other cyanopyridines have been obtained. The physical data are
recorded in Table No. 4.
[E] Antimicrobial activity of 2-Amino-3-cyano-4-[1',N-phenyl-3'-p-
fluorophenyl pyrazole-4'-yl]-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.4.
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TABLE NO. 4 : PHYSICAL CONSTANTS OF 2-AMINO-3-CYANO-4-[1' ,N-PHENYL-3'-p-FLUOROPHENYL
PYRAZOL-4'-YL]-6-ARYL PYRIDINE
Sr.
No.
1
4a C6H5- C27H18FN5 431 164 0.51 67 16.23 16.16
4b 4-OCH3-C6H4- C28H20FN5O 461 234 0.61 65 15.18 15.11
4c 4-CH3-C6H4- C28H20FN5 445 157 0.49 57 15.27 15.19
4d 4-Cl-C6H4- C27H17ClFN5 465 142 0.53 63 15.03 14.96
4e 4-F-C6H4- C27H17F2N5 449 191 0.57 59 15.58 15.52
4f 4-OH-C6H4- C27H18FN5O 447 189 0.47 72 15.65 15.57
4g 2-OH-C6H4- C27H18FN5O 447 171 0.53 67 15.65 15.58
4h 4-NO2-C6H4- C27H17FN6O2 476 162 0.69 68 17.64 17.58
4i 3-NO2-C6H4- C27H17FN6O2 476 180 0.71 64 17.64 17.56
4j 4-Br-C6H4- C27H17BrFN5 510 174 0.50 66 17.72 17.65
4k 4-NH2-C6H4 C27H19FN6 446 194 0.64 60 18.82 18.75
4l C4H3S- C25H16FN5S 437 205 0.58 69 16.01 15.94
*TLC Solvent System : Ethyl acetate : Hexane
2 : 8
Rf*
Value
6
Yield
%
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GRAPHYCAL CHART NO.4: ANTIMICROBIAL ACTIVITY OF 2-AMINO-3-CYANO- 4-[1’N-PHE NYL-3’-p-FLUOROPHENYL PYRAZOL-4’-
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P. vulgaris 20 19 9 11 10 20 17 15 12 12 11 17 16 19 15 21 0
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of cyanopyridines (type-IV) revealed that most of
the compounds were able to inhibit the growth of Gram positive and Gram negative
bacterial strains.
Maximum activity was observed in compounds bearing R=4-aminophenyl,
4-methylphenyl & thienyl and significant activity was displayed by compounds
bearing R=phenyl, 4-fluorophenyl and 4-bromophenyl against Gram positive
bacterial strains B. cocous and B. subtillus
While in case of Gram negative bacterial strains E. coli & P. vulgaris,
highest activity was observed in compounds bearing R=phenyl and 4-
methoxyphenyl and significant activity was displayed by compounds bearing 4-
hydroxyphenyl & thienyl.
ANTIFUNGAL ACTIVITY
Most of the cyanopyridines were mildly active against fungal strain A. niger.
The maximum activity was displayed by compound bearing R=4-chlorophenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-METHOXY-3-
CYANO-4-[1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-6-
ARYL PYRIDINES
The pyridine nucleus is found in a large number of commonly used drugs
which have diverse pharmacological activities. To achieving better drug potency
cyano pyridine derivatives of type (V) have been prepared by the condensation
of chalcones of type (I) with malononitrile in presence of sodium methoxide.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
R = ArylType - (V)
N
N
O
R
F
CH2.(CN)2
N
N
F
N
R
H3CO
N
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IR SPECTRAL STUDY OF 2-METHOXY-3-CYANO-4- (1 ' ,N-PHENYL-3 ' -p -
FLUOROPHENYL-PYRAZOL-4'-YL)-6-ANISYL PYRIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2922 2975–2920 426
–CH
3
C – H str. (sym.) 2852 2880–2840 "
C – H def.(asym.) 1458 1470–1435 "
C – H def.(sym.) 1367 1385–1350 "
Aromatic C – H str. 3058 3080–3030 427
C – H i.p. (def.) 1047 1070–1000 "
C – H o.o.p (def.) 823 835–810 "
Pyrazole C = N str. 1589 1650–1585 428
ring C = C str. 1542 1585–1480 "
C – N str. 1222 1350-1200 "
C – F str. 756 750–700 "
Ether C – O – C str. (asym.) 1218 1275–1200 "
Pyridine C ≡ N str. 2221 2240–2120 429
ring C = N str. 1560 1650–1550 "
C = C str. 1504 1585-1480 "
N
N F
N
H3CO
N
OCH3
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PMR SPECTRAL STUDY OF  2-METHOXY-3-CYANO-4-(1 ' ,N-PHENYL-3 ' -p-
FLUOROPHENYL-4'-YL)-6-(p-ANISYL)-PYRIDINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.85 3H singlet Ar-OCH
3(1)
-
2. 4.18 3H singlet OCH
3(2)
-
3. 6.90-6.94 2H doublet Ar-Hgg' Jgf=10.2
4. 7.06-7.13 3H triplet Ar-Hdd'+Hh Jde = 6.9
5. 7.34-7.39 1H triplet Ar-Ha -
6. 7.47-7.50 2H doublet Ar-Hbb' Jbc=10.2
7. 7.53-7.58 2H multiplet Ar-Hcc' -
8. 7.73-7.81 4H d.doublet Ar-Hff' + Hee' Jfg=8.1
Jed=8.7
9. 8.47 1H singlet CHx -
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-METHOXY-3-
CYANO-4-[1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-6-
ARYL PYRIDINES
[A] Synthesis of N-Aminophenyl-α-methyl-p-fluorophenyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-phenyl-3-(1'-N-phenyl-3'-p-fluorophenyl-pyrazol-4'-
yl)-2-propene-1-one
See Part-I, Section-I (C).
[D] Synthesis of 2-Methoxy-3-cyano-4-[1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl]-6-anisyl-pyridine
A mixture of 1-anisyl-3-(1',N-phenyl)-3'-p-fluorophenyl pyrazol-4'-yl)-2-
porpene-1-one (3.98 g, 0.01M), malononitrile (0.66 g, 0.01 M) and sodium
methoxide (10 ml) (6.61g, 0.08M) dissolved in absoulte alcohol was refluxed for
10 hrs. in water bath at temp 70oC. The reaction product was poured into ice,
crude product was isolated, crystallised from ethanol. Yield 70%, m.p. 270oC
(C29H21FN4O2 ; Found : C, 73.04%; H, 4.36%; N, 11.68%; Requires : C, 73.10%;
H, 4.44%; N, 11.76%).
Similarly other cyanopyridines have been obtained. The physical data are
recorded in Table No. 5.
[E] Therapeutic activity of 2-Methoxy-3-cyano-4-[1',N-phenyl-
3'-p-fluorophenyl pyrazol-4'-yl]-6-aryl-pyridines
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No.5.
Antitubercular  screening of the compounds of type(V) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-I
(D) and the percentage of inhibition data of the compounds are recorded in Table
No. 5a.
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TABLE NO. 5 : PHYSICAL CONSTANTS OF 2-METHOXY-3-CYANO-4-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-6-ARYL PYRIDINES
Sr.
No.
1
5a C6H5- C28H19FN4O 446 240 0.42 61 12.55 12.49
5b 4-OCH3-C6H4- C29H21FN4O2 476 270 0.65 70 11.76 11.68
5c 4-CH3-C6H4- C29H21FN4O 460 237 0.67 60 12.17 12.10
5d 4-Cl-C6H4- C28H18ClFN4O 480 231 0.57 63 11.65 10.58
5e 4-F-C6H4- C28H18F2N4O 464 128 0.60 64 12.06 12.00
5f 4-OH-C6H4- C28H19FN4O2 462 148 0.47 59 12.11 12.07
5g 2-OH-C6H4- C28H19FN4O2 462 177 0.51 65 12.11 12.05
5h 4-NO2-C6H4- C28H18FN5O3 491 201 0.53 69 14.25 14.16
5i 3-NO2-C6H4- C28H18FN5O3 491 211 0.49 63 14.25 14.17
5j 4-Br-C6H4- C28H18BrFN4O 525 266 0.50 64 10.66 10.59
5k 4-NH2-C6H4 C28H20FN5O 461 166 0.59 68 15.18 15.11
5l C4H3S- C26H17FN4OS 452 243 0.67 65 12.38 12.32
*TLC Solvent System : Ethyl acetate : Hexane
2 : 8
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of 2-methoxy-3-cyanopyridines (type-V) revealed
that most of the compounds were able to inhibit the growth of Gram positive &
Gram negative bacterial strains.
Maximum activity was displayed by compounds bearing R=phenyl & 4-
hydroxyphenyl and significant activity was displayed by compounds bearing R=4-
methylphenyl & 4-chlorophenyl against  Gram posi t ive bacter ial  s trains
B. cocous and B. subtillus
While in case of Gram negative bacterial strains, maximum activity was
observed in compound containing R=4-methylphenyl and 4-nitrophenyl &
signif icant activity was displayed by compounds bearing R=phenyl, 4-
methylphenyl, 4-hydroxyphenyl and 3-nitrophenyl against E. coli & P. vulgaris.
ANTIFUNGAL ACTIVITY
All the compound are mild to moderately active against fungal strain
A. niger . Maximum activity was displayed by compound bearing R=4-
methoxyphenyl.
The antimicrobial activity shown by compounds was comparable with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
Al l  t he  compounds  d i sp layed  ac t i v i t y ,  r ang ing  f rom 2  to  95%
inhibit ion against Mycobacterium tuberculosis H37Rv .  Compounds
with R = 4-methoxyphenyl, 4-fluorophenyl and thienyl exhibited maximum
activity upto 95% inhibition.
TABLE NO. 5a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
Corp
ID
Sample
ID
CommentAssay
295634 HCV-128 C
6
H
5
- Alamar H
37
Rv >6.25 67 - MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295635 HCV-129 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv <6.25 95 + "
295636 HCV-130 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 2 - "
295637 HCV-131 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 5 - "
295638 HCV-132 4-F- C
6
H
4
- Alamar H
37
Rv <6.25 92 + "
295639 HCV-133 4-OH- C
6
H
4
- Alamar H
37
Rv >6.25 73 - "
295640 HCV-134 2-OH- C
6
H
4
- Alamar H
37
Rv >6.25 88 - "
295641 HCV-135 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295642 HCV-136 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 16 - "
295643 HCV-137 4-Br--C
6
H
4
- Alamar H
37
Rv >6.25 12 - "
295644 HCV-138 4-NH
2
-C
6
H
4
- Alamar H
37
Rv >6.25 76 - "
295645 HCV-139 C
4
H
3
S- Alamar H
37
Rv <6.25 94 + "
MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
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  PART-III
  STUDIES ON
   THIAZOLIDINONES
INTRODUCTION
Thiazolidinones are derivatives of thiazolidines with carbonyl gp at position
2(I), 4(II) or 5(III) have been a great success in the field of chemistry and
pharmacology. They are an integral par t of pharmaceutically impor tant
compounds like penicillins. Substituted thiazolidinone derivatives represent
important key intermediates for the synthesis of pharmacologically active drugs.
SYNTHETIC ASPECTS
Several methods for the preparation of 4-thiazolidinones are narrated in
literature136-143.
1. Jerome Blanchet  & J ieping-Zhu144 have synthes i sed 2- imino-4-
thiazolidinones (IV) derivatives by the condensation of aldehyde, chloroform
and thiourea.
2. R. Nath and K. Shankar145 have prepared 4-thiazolidinones (V) by
cyclisation of N-aryl-N'-(2'-pyridyl) thiocarbamide with chloroacetic acid.
(I) (II) (III)
N
H
S O
NH
S
O
N
H
SO
R
O
H
Cl3CCO2H
Cl3CCO2Na
DMF, 20  Co
R
OH
CCl3
thiourea
NaOH
DMF, H2O
120  C
o
NH
S
R
O
NH
(IV)
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3. I. D. Shah and J. P. Trivedi146 have synthesised thiazolidinones (VI) from 4-
aryl-thiosemicarbazones by condensed them with chloroacetic acid, α-
bromopropionic acid and α-bromophenyl acetic acids.
4. M. Saeda et. al.147 have synthesised some new thiazolidinones.
MECHANISM
The reaction of 4-thiazolidinones proceeds by the attacks of the chloroacetic
acid upon the C=S group. The tautomerism takes place with removal of HCl
followed by removal of water and subsequent cyclisation.
R' NH
S
NH
R
Cl.CH2COOH
N
N
S
N
R
O
(V)
R'
NH NH
S
N R''
R-CH-COOH N
S
O
N
N
R'
R
R''
Br
(VI)
R, R' = Aryl
R' = H, Ph, CH3, R'' = Aryl
R
NH N
R
SH
R
NH NH
R
S
OH
Cl
O
-HCl
S
N
O
R
N R
-H2O
S
O
N R
NH
R
OH
R = Aryl
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THERAPEUTIC IMPORTANCE
Much research has been carried out with an aim to finding therapeutic values
of thiazolidinone skeleton since their discovery. The thiazolidinones, substituted
at 2- and 3-positions are reported to exhibit a wide variety of biological activity.
1. Anthelmintics148,149
2. Cardiovascular150
3. Mosquito repellant151
4. Antiviral152
5. Local anaesthetic153
6. Antitumor154
7. Antitubercular155,156
8. Anti HIV & anticancer157
9. Antimicrobial158
10. Herbicidal159
Kato Y. & co-workers160 have discovered thiazolidinones (VII) as a novel
non-peptide thrombin receptor anatagonist. Abbas S. F. & co-workers161 have
synthesised thiazolidinone derivatives which have been found to possess
antimicrobial activity.
Romulo P. Tenorio et. al.162 have prepared & shown anti-toxoplasma gondii
activity of thiazolidinones derivatives (VII). Veeresa Gududuru & co-workers163
have synthesised thiazolidinones (IX) to study their antiproliferative activity for
prostate cancer.
N
S
N
O Cl
Cl
Cl
O
OH3CO
(VII)
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C. Bonde & co-workers164 have synthesised pyraz ine containing
thiazolidinones (X) as antimicrobial agents. A. Rao & co-workers165 have
discovered thiazolidinones derivatives as non-nucleoside HIV-1 reverse
transcriptase inhibitors.
Some antioxidant activity of thiazolidinones have been studied by Mei-Hsiu
Shih & Fang-Ying Ke166. Aaron S. Anderson et.  a l .167 have prepared
thiazolidinones (XI) as CCR4 antagonists.
G. S. Gadaginamath et. al.168 have prepared thiazolidinones as antimicrobial
agent. R. S. Lodhi and co-workers169 have synthesised and studied antimicrobial,
antiinflammatory and analgesic property of 4-thiazolidinones and aryledene
derivatives (XII)
N
N
N
S
N
R
ONH
CO
OCH2
(X)
S
N
O
CO2HN
N
R1
O2N
(VIII) (IX)
N
S
O
NH
Aryl
O
(CH2)n
CH3
N
O
NH CH3
ClCl
Cl
O
O
NH
N
(XI)
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Pawar and co-workers170 have reported synthesis and in vitro antibacterial
activity of some 4-thiazolidinone derivatives. Richard E. Lee. et. al.171 have
synthesised & shown thiazolidinones (XIII) as inhibitors of Mycobacterium
tuberculosis. 5-Arylidene-4-thiazolidinediones (XIV) have been found as aldose
reductase inhibitors by Rosanna Maccari et. al.172.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have synthesised variety of 4-thiazolidinone derivatives bearing
s-triazine173, sulphonamido benzylamino174,  aryl substituted hydroxy and β,β-
dichloro ethylamino phenyl moieties of 4-thiazolidinone ring system and have
reported as potent antimicrobial agent.
H. H. Parekh and co-workers have synthesised 4-thiazolidinones bearing
acridine-9-yl175, 6-hydroxy pyrimidine176, 9-thiazolidinone ring system having
antimicrobial activity.
D. G. Joshi & co-workers177 have synthesised novel thiazolidinone
derivatives as antitubercular agents. N. J. Datta & co-workers178 have
demonstated  thiazolidinones as biologically active agent. A. H. Bapodara & co-
workers179 have prepared 4-thiazolidinones & showing their biological activity.
N
N
NH N S
R1
O
ZO
(XII)
R1 = aryl
Z = alkyl / aryl
S
N
R3
O
R2
OH O
R1
(XIII)
R1 = alkyl
R2,R3 = aryl
N
S
H
Ar
O
R
O
(XIV) R = aryl
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Multiple biological activities of 4-thiazolidinones have been discovered by
S. B. Hirpara & co-workers180.
Moreover, A. J. Baxi et. al.181 have synthesised some new 4-thiazolidinones
which shows anti-HIV, antitumor and antihypertensive activities. Recently, A. R.
Parikh and co-workers182 have assessed thiazolidinone derivatives bearing 7-
methoxyquinoline nucleus for antimicrobial activity.
Siddique, Mohammad et. al.183 have prepared substituted thiazolidinones
and reported their antibacterial, antifungal, antithyroid and amoebicidal properties
(XV).
Considerable evidence has been accumulated to demonstrate the wide
applications of thiazolidinone derivatives. In view of these findings, it appeared
of interest to synthesise newer thiazolidinone derivatives with better potency.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-
ARYLIMINO-3 ,N -ARYL-5 - [1 , 'N -PHENYL-3 ' -p -
FLUOROPHENYL-4' -PYRAZOLYL-METHINO]-4-
THIAZOLIDINONES
N
S
O
S
R5
R4
R3
R1
R2
R1 = OH, R2, R4, R5 = H, R3 = Me
(XV)
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5 - [1 ' ,N -PHENYL-3 ' -p -FLUOROPHENYL-4 ' -PYRAZOLYL
METHINO]-4-THIAZOLIDINONES
Recently much interest has been foucused on the synthesis and biodynamic
activities of arylidene and it is a good synthon for various heterocyclic rings.
With a view to obtaining compounds having better therapeutic activities, we have
synthesised 2-arylimino-3-N-aryl-5-(1',N-phenyl-3'-p-fluorophenyl-4'-pyrazol
methino)-4-thiazolidinones by the condensation of pyrazole aldehyde with
various thiazolidinone derivatives.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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IR SPECTRAL STUDY OF 2-(p-TOLYLIMINO)-3,N-(p-TOLYL)-5-(1',N-PHENYL-3'-p-
FLUOROPHENYL-4'-PYRAZOLYL METHINO)-4-THIAZOLIDINONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975–2920 426
–CH
3
C – H str. (sym.) 2848 2880–2830 "
C – H def. (asym.) 1446 1470–1435 "
C – H def. (sym.) 1338 1385–1330 "
Aromatic C – H str. 3018 3080–3050 427
C – H i.p. (def.) 1118 1125–1090 "
1062 1070–1000 "
C – H o.o.p (def.) 829 835–810 "
Pyrazole C = N str. 1600 1650–1600 428
ring C = C str. 1537 1585–1480 "
C – N str. 1226 1350–1200 "
C – F str. 758 750–700 "
Thiazolidinone C = O str. 1104 1760–1655 430
ring C = N str. 1581 1650–1590 "
C – S – C str. 678 700–600 "
S
N
N
N
F
N
O
CH3
CH3
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PMR SPECTRAL STUDY OF 2-(p-TOLYL) IMINO-3,-N-(p-TOLYL)-5-(1',N-PHENYL-3'-p-
FLUOROPHENYL-4'-PYRAZOLYLMETHINO)-4-THIAZOLIDINONES
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 2.36 3H singlet Ar-CH
3
-
2. 2.47 3H singlet Ar-CH
3
-
3. 6.87-6.89 2H doublet Ar-Hgg' Jgf=7.8
4. 7.76-7.20 4H quartet Ar-Hii' + Hdd' -
5. 7.34-7.36 5H triplet Ar-Hff'+Hhh'+Ha -
6. 7.46-7.52 2H triplet Ar-Hbb' -
7. 7.62-7.67 2H quartet Ar-Hcc' -
8. 7.73-7.78 3H triplet Ar-Hee'+CHj Jed=7.8
9. 8.09 1H singlet CHx -
S
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N
N
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CH3
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c
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x
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-ARYLIMINO-3,N-
ARYL-5 - (1 ' ,N -PHENYL-3 ' -p -FLUOROPHENYL-4 ' -PYRAZOLYL
METHINO)-4-THIAZOLIDINONES
[A] Preparation of N1, N3-Bis-p-tolyl thiourea184
In a round bottom flask, a mixture of p. toludine (0.2M), carbon disulphide
(7ml, 0.01M) and absolute alcohol for 5-6 hrs. at temp 40oC. On completion of
reaction, the excess of carbon disulphide and alcohol was removed by distillation.
The product was treated with hydrochloric acid to remove excess of amine present
and crude product was isolated and crystallised from ethanol. m.p. 193oC.
[B] Preparation of 2-Tolylimino-3-tolyl-5H-4-thiazolidinones185
A solution of N1, N3-bis-p-tolyl thiourea (0.01M) and chloroacetic acid
(0.94g, 0.01M) in glacial acetic acid (15 ml) was refluxed with fused sodium
acetate (1.25g, 0.015M) for 5 hrs. The reaction product was poured in water,
kept overnight, crude product was isolated and crystallised from ethanol. m.p.
164oC.
[C] Preparation of 2-(p-Tolylimino)-3-(p-tolyl)-5-(1',N-phenyl-3'-p-
fluorophenyl-4'-pyrazolyl methino)-4-thiazolidinone
A mixture of 2-(p-tolylimino)-3-(p-tolyl)-5H-4-thiazolidinone (2.69g, 0.01M)
1,N-phenyl-3-p-fluorophenyl-4-formyl pyrazole (2.65g, 0.01M) and fused sodium
acetate (1.25g, 0.015M) was refluxed in glacial acetic acid (15 ml) for 4-5hrs. at
temp 120oC. cooled, poured into water and treated with ammonia to remove
excess of glacial acetic acid. The product was isolated and crystallised from
ethanol. yield 75% m.p. 230oC (C33H25FN4OS : Found : C, 72.72%; H, 4.58%;
N, 10.25% Requires : C, 72.77%; H, 4.63%; N, 10.29%).
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Similarly other substituted thiazolidinones have been prepared. The physical
data are recorded in Table No. 6.
[D] Therapeutic activity of 2-Arylimino-3,N-aryl-5-(1',N-phenyl-3'-p-
fluorophenyl-4'-pyrazolylmethino)-4-thiazolidinones
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.6.
The antitubercular  screening of the compounds of type(VI) were carried
out by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are recorded
in Table No. 6a.
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TABLE NO. 6 : PHYSICAL CONSTANTS OF 2-ARYLIMINO-3,N-ARYL-5-[1',N-PHENYL-3'-p-FLUOROPHENYL-
4'-PYRAZOLYL METHINO]-4-THIAZOLIDINONES
Sr.
No.
1
6a C6H5- C32H21FN4OS 516 238 0.56 68 10.85 10.79
6b 4-OCH3-C6H4- C33H25FN4O3S 576 208 0.51 69 9.72 9.66
6c 4-CH3-C6H4- C33H25FN4OS 544 230 0.53 75 10.29 10.25
6d 4-Cl-C6H4- C31H19Cl2FN4OS 585 211 0.64 71 9.57 9.51
6e 4-F-C6H4- C31H19F3N4OS 552 220 0.58 70 10.14 10.09
6f 3-Cl,4-F-C6H3- C31H17Cl2F3N4OS 621 218 0.41 75 9.02 8.97
6g 3-NO2-C6H4- C31H19FN6O5S 606 214 0.72 66 13.83 13.78
6h 2-NO2-C6H4- C31H19FN6O5S 606 216 0.75 64 13.83 13.76
6i 3,4-(Cl)2-C6H3- C31H17Cl4FN4OS 654 201 0.65 74 8.86 8.80
6j 4-Br-C6H4- C31H19Br2FN4OS 674 225 0.60 67 8.31 8.26
6k 2,4-(CH3)2-C6H3- C35H29FN4OS 572 208 0.71 69 9.78 9.71
6l 2,5-(Cl)2-C6H3 C31H17Cl4FN4OS 654 234 0.42 71 8.56 8.49
*TLC Solvent System : Acetone : Benzene
2.5 : 7.5
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of thiazolidinones (type-VI) revealed that
compounds were mild to moderately active against Gram positive and Gram
negative bacterial strains.
Maximum activity was displayed by compounds bearing R=4-methylphenyl
and 2-nitrophenyl and 2,4-dimethyl phenyl against Gram positive bacterial strains
B. cocous & B. subtillus. Other compounds were less active against these
bacterial strains.
In case of Gram negative bacterail strains E. coli & P. vulgaris, maximum
activity was observed in compounds bearing R=3-chloro,4-fluorophenyl and
significant activity was displayed by compounds bearing R=4-chlorophenyl and
3-nitrophenyl against these bacterial strains.
ANTIFUNGAL ACTIVITY
All the compounds are less active against fungal strain A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
All the compounds displayed antitubercular activity, ranging from 8 to
95% inhibition against Mycobacterium tuberculosis H37Rv. Compound
with R = phenyl substituent exhibited maximum activity i.e. 95% inhibition.
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TABLE NO. 6a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
295610 HCV-104 C
6
H
5
- Alamar H
37
Rv <6.25 95 + MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295611 HCV-105 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 11 - "
295612 HCV-106 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 14 - "
295613 HCV-107 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 8 - "
295614 HCV-108 4-F-C
6
H
4
- Alamar H
37
Rv >6.25 16 - "
295615 HCV-109 3-Cl,4-F-C
6
H
3
- Alamar H
37
Rv >6.25 23 - "
295616 HCV-110 3-NO
2
- C
6
H
4
- Alamar H
37
Rv >6.25 20 - "
295617 HCV-111 2-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295618 HCV-112 3/4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 9 - "
295619 HCV-113 4-Br-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295620 HCV-114 2/4-(CH
3
)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 22 - "
295621 HCV-115 2/5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
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   PART-IV
  STUDIES ON
   PYRIMIDINONES
INTRODUCTION
Pyrimidine a heterocycle, containing nitrogen atoms at position 1 & 3 in
six membered ring have been subject of substantial attention by synthetic &
medicinal chemists because of the role of this heteroaromatic ring sustain in many
biological  system l ike nucleic acid (DNA, RNA) and co-enzymes. e.g.
fluorouracil186,187(I) which has been used in cancer treatment.
Some pyrimidines physiologically as well as pharmacologically important
are as under. eg. cytosine (II), bedmethrin (III), blasticidine (IV).
Synthetic pyrimidinone derivatives contribute much to the searchable
literature of pyrimidinone derivatives in huge libraries owing to their wide
applicability in different fields.
SYNTHESIS ASPECTS
Different methods for the synthesis of pyrimidinones have been cited in the
literature188 are as under.
N
H
NH
F
O
O
(I)
N
H
N
O
NH2
(II)
N
N
NH2
O
HOH2C
CH3(III)
N
N O
O
COOH
NH
O NH2
NH2
NH
CH3
(IV)
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1. Bigi and co-worker189 have synthesised pyrimidinones as shown below
under solvent free condition.
MECHANISM
THERAPEUTIC IMPORTANCE
Pyrimidine derivatives have been proved to be of great importance in
exhibiting and enhancing the biological activities such as
1. Antitumor190
H5C2OOC
CH3
O
Ph-CHO,H2O
NH2 NH2
O
N
H
N
H
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N S
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. .
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2. Carcinostatic191
3. Antiinflammatory and anticonvulsant192,193
4. Antimalarial194
5. Antithyroid195
6. Anthelmintic196
7. AntiHIV197,198
8. Antilishmential199
9. Antiviral200
10. Antimicrobial201
11. Herbicidal202
12. Antagonists203-205
Moreover Norman M. H. et. al.206 have  synthesised pyrimidine derivatives
as neuropeptide Y5 receptor antagonists. Azaryan et. al.207 have synthesised
pyrimidine diones as antitumor agent. Krivongov and co-workers208 have
synthes i sed pyr imid inone der iva t ives  possess ing  immunot rop ic  and
antiinflammatory activity. Richard J. Perneu et. al.209 have discovered pyrimidine
derivatives (VI) as adenosine kinase inhibitors. Sharad Verma et. al.210 have
prepared pyrimidines (VII) as cyclin-dependent kinase inhibitors.
Timothy and co-workers211 have suggested imidazolyl pyrimidinones as
antiviral. Amjad Ali et. al.212 have synthesised new fused pyrimidinones as
antimicrobial agents. Antonello Mai et. al.213 have synthesised pyrimidine
derivative (VIII) as non-nucleoside reverse transcriptase inhibitors. Yari M. M. and
co-workers214 have investigated the pyrimidinone derivatives which possess
calcium antagonist activity.
N
N
N
R
Ar
HNH2
(VI) R = Aryl / Alkyl
N
N
NH NH
N
NH R1
R2
(VII)
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Baraldi P. G. et. al.215 have discovered triazolo [1,5-c] pyrimidine derivatives
as a new class of A2A adenosine receptor antagonists. Balis F. M. et. al.
216 has
investigated pyrimidines (IX) used in the treatment of leukamia in childhood.
Amuti Kofies et. al.217 have suggested pyrimidinones as herbicidal and plant
growth regulators. K. Mogilaiah et. al.218 have prepared spiropyrimidinones as
antibacterial. Anu Agarwal co-workers219 have discovered pyrimidines (X) as
antimalarial agent.
Aleem Gangiee & co-workers220 have prepared pyrimidinone derivatives
(XI) as non classical antitolate inhibitors of thymidylate synthase. Bruce M. A &
co-workers221 have prepared the dihydro pyrimidinones as NPY antagonist. Mona
Mahran and co-workers222 have reported pyrimidine derivatives as potent
antimicrobial and antitumor agent. Viney Hather & A. K. Madan223 have prepared
pyrimidinones(XII) as anti-HIV agents.
N
NH
FF
R
O
NH
X
R1
(VIII)
R = R1 = H, Me
X = Alkyl / Aryl/ Aryl alkyl
(IX)
N
N
N
H
N N
CH3
NH2
NH2
O
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COO
COO
-
-
N
N
N
N
O
R
(X)
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Tsann-Long Su et. al.224 have reported pyrimidines (XIII) as antitumor agents.
Recently, Michael Deininger & co-workers225 have discovered pyrimidines (XIV)
named (imatinib) as a therapeutic agent for chronic myloid leukemia. Saxena A.
K. & co-workers226 have prepared 2,6-disubstituted pyrimidinones as CNS agent.
Barbuliene M. M. et. al.227 have synthesised pyrimidinones as antiinflammatory
agent.
N
NH
N
H
SO
NH2
OH3
X
(XI)
X = C, Cl, Br, CN, NO2, CF3, OCF3
N
NH
R1
RS
X
O
(XII)
N
N
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NH2
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N
R2
(XIII)
R1 = NH2, OH
R2 = H, Me, NO2, CN, F, Cl, Br
N
N
N
NH
CH3 NH
O
N N NH2
(XIV)
107
Antitumor activity of new pyrimidinone of sesquiterpene lactones has been
found by Angelina Quintero et. al.228. Patricia F. F. et. al.229 have synthesised
and screened for their leukocyte functions inhibitor activity. Dumas Jacques et.
al.230 have synthesised pyrimidinones and tested their hyperproliferative disorder
activity.
Thus, diverse biological activities have been encountered in compounds
containing pyrimidinone ring system. To further assess the potential of such type
of compounds, study of pyrimidinones have been  undertaken as under.
SECTION - I : SYNTHESIS AND THERAPEUTIC EVALUATION OF
6-ARYLIMINO-7,N-ARYL-2-OXO-4-(1',N-PHENYL-3'-
p -FLUOROPHENYL-PYRAZOL-4 ' -YL ] -1 ,2 ,3 ,4 -
T E T R A H Y D R O T H I A Z O L I D I N O - [ 4 , 5 - d ] -
PYRIMIDINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-OXO-4-(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-
YL),1,2,3,4-TETRAHYDRO THIAZOLIDINO-[4,5-d]-PYRIMIDINES
In the past years considerable evidence has been accumulated to
demonstrate the efficiency of pyrimidinones. It was considered worthwhile to
synthesise compounds bear ing 2-aryl imino-3-aryl-5-(1 ' ,N-phenyl-3 ' -p-
fluorophenyl-4'-pyrazolylmethino)-4-thiazolidinones of type (VII) which have
been prepared by the condensation of 2-arylimino-3-aryl-5H-4-thiazolidinone,
1,N-phenyl-3-p-fluoro-phenyl-4-formyl-pyrazole and urea in presence of catalytic
amount of conc. HCl as shown under.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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IR SPECTRAL STUDY OF 6-(p-ANISYLIMINO)-7,N-(p-ANISYL)-2-OXO-4-(1',N-PHENYL-
3'-p-FLUOROPHENYL-PYRAZOL-4'-YL)-1,2,3,4-TETRAHYDRO-THIAZOLIDINON-[4,5-
d]-PYRIMIDINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2958 2975–2950 426
–CH
3
C – H str. (sym.) 2844 2880–2840 "
C – H def. (asym.) 1444 1470–1435 "
C – H def. (sym.) 1359 1395–1370 "
Aromatic C – H str. 3082 3090–3030 427
C – H str. 1444 1520–1440 "
C – H i.p. (def.) 1151 1125–1090 "
1028 1070–1000 "
C – H o.o.p (def.) 831 835–810 "
Pyrazole C = N str. 1616 1610–1590 428
ring C – N str. 1224 1230–1020 "
C = C str. 1444 1585-1450 "
C – F str. 758 760-710 "
Ether C – O – C str. (asym.) 1249 1275–1200 "
Pyrimidine C = O str. 1708 1750–1600 431
ring N – H str. 3396 3500–3350 "
C = N str. 1627 1650–1550 "
C – S – C str. 758 800–700 "
0.0
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40.0
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100.0
%T
500.0750.01000.01250.01500.01750.02000.03250.0
1/cmoxopyrimidine-ar-och3 cry
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PMR SPECTRAL STUDY OF  6-(p-ANISYLIMINO)-7,N-(p-ANISYL)-2-OXO-4-[1',N-
PHENYL-3 ' -P-FLUOROPHENYL PYRAZOL-4 ' -YL] -1 ,2 ,3 ,4 -TETRAHYDRO
THIAZOLIDINO-[4,5,d]-PYRIMIDINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 3.82 3H singlet Ar-OCH
3
-
2. 3.84 3H singlet Ar-OCH
3
-
3. 6.89-6.95 4H singlet Ar-Hgg' + Hjj' -
4. 7.02-7.05 2H doublet Ar-Hdd' Jde=8.9
5. 7.15-7.20 2H triplet Ar-Hbb' -
6. 7.33-7.39 3H doublet Ar-Hhh' + Ha Jhi=8.7
7. 7.47-7.52 2H triplet Ar-Hff' -
8. 7.62-7.67 2H quartet Ar-Hcc' -
9. 7.73-7.78 3H triplet Ar-Hee' + CHj Jed=8.1
10. 8.09 1H singlet CHx
N N
F
NH
N
H
S
N
N
O
H3CO
H3CO
a b
c
c'
b'
d
e
d'
e'
f
g
g'
f'
h'
i
hi'
j
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EXPANDED AROMATIC REGION
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m/z = 620 (m+2)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYLIMINO-7,N-
ARYL-2-OXO-4-[1',N-PHENYL-3'-p-FLUOROPHENYL-PYRAZOL-4'-YL]-
1,2,3,4-TETRAHYDRO-THIAZOLIDINO-[4,5-d]-PYRIMIDINES
[A] Preparation of 2-p-anisylimino-3-anisyl-5H-4-thiazolidinone
See, Part-III, Section-I (A)
[B] Preparation of 6-(p-anisylimino)-7,N-(p-anisyl)-2-oxo-4-(1',N-
phenyl -3 ' -p - f luorophenyl -pyrazol -4 ' -y l ) -1,2,3,4 tetrahydro
thiazolidino-[4,5-d]-pyrimidine
A mixture of 2-(p-anisylimino)-3-(p-anisyl)-5H-4-thiazolidinone (3.28g,
0.01M) 1,N-phenyl-3-p-fluorophenyl-4-formyl-pyrazole (2.65g, 0.01M) and urea
(0.60g, 0.01M) were taken in methanol (30 ml) and a catalytic amount of con.
HCl (0.5 ml) was added. The reaction mixture was refluxed for 5 hrs, at temp
60o-70oC cooled, poured into water. The product was isolated and crystallised
from methanol-DMF. Yield 70%, m.p. 222oC (C34H27FN6O3S, Found : C, 65.92%;
H, 4.33%; N, 13.50% Requires : C, 66.01%; H,4.40%; N, 13.58%;).
Similarly other pyrimidines were prepared. The physical data are recorded
in Table No. 7.
[C] Therapeutical activity of 6-Arylimino-7,N-aryl-2-oxo-4-(1',N-phenyl-
3'-p-fluorophenyl-pyrazol-4'-yl)-1,2,3,4-tetrahydro-thiazolidino-
(4,5-d)-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I(D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.7.
Antitubercular  screening of the compounds of type(VII) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are
recorded in Table No. 7a.
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% of Nitrogen
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8
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TABLE NO. 7 : PHYSICAL CONSTANTS OF 6-ARYLIMINO-7,N-ARYL-2-OXO-4- [1 ' -N-PHENYL-3 ' -p -
FLUOROPHENYL-PYRAZOL-4'-YL]-1,2,3,4-TETRAHYDRO-THIAZOLIDINO [4,5,-d]-PYRIMIDINES
Sr.
No.
1
7a C6H5- C32H23FN6OS 558 194 0.57 60 15.04 14.91
7b 4-OCH3-C6H4- C34H27FN6O3S 618 222 0.67 70 13.58 13.50
7c 4-CH3-C6H4- C34H27FN6OS 576 207 0.49 64 14.32 14.21
7d 4-Cl-C6H4- C32H21Cl2FN6OS 627 186 0.52 65 13.39 13.26
7e 4-F-C6H4- C32H21F3N6OS 594 178 0.53 69 14.13 14.03
7f 3-Cl,4-F-C6H3- C32H19Cl2F3N6OS 663 167 0.51 59 12.67 12.53
7g 3-NO2-C6H4- C32H21FN8O5S 648 201 0.59 60 17.28 17.10
7h 2-NO2-C6H4- C32H21FN8O5S 648 236 0.60 62 17.28 17.13
7i 3,4-(Cl)2-C6H3- C33H19Cl4FN6OS 696 190 0.56 67 12.07 11.97
7j 4-Br-C6H4- C32H21Br2FN6OS 716 229 0.61 63 11.73 11.64
7k 2,4-(CH3)2-C6H3- C36H31FN6OS 614 163 0.64 60 13.67 13.57
7l 2,5-(Cl)2-C6H3- C32H19Cl4FN6OS 696 172 0.66 71 12.07 11.94
*TLC Solvent System : Acetone : Benzene
2 : 8 (7a-7d, 7i-7k)
3 : 7 (7e-7h, 7l)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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GRAPHYCAL CHART NO.7: ANTIMICROBIAL ACTIVITY OF 6-ARYLIMINO-7,N-  ARYL-2-OXO-4- [1’N-PHE NYL-3’-p-FLUOROPHENYL PYRAZOL-4’-YL]
1,2,3,4-TETRAHYDRO-THIAZOLIDINO(4,5-d)-PYRIMIDINES.
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B. cocous 17 14 11 22 7 17 13 11 14 16 9 10 17 21 16 23 0
B. subtillus 14 19 11 16 14 13 12 17 7 17 19 11 15 21 22 19 0
E. coli 17 11 9 14 11 16 19 14 13 12 10 18 19 18 20 22 0
P. vulgaris 22 17 13 15 14 17 16 9 14 11 13 17 16 19 15 21 0
A. niger 18 14 14 18 12 21 7 11 13 15 17 14 0 0 0 0 26
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of pyrimidinones (type-VII) revealed that most of
the compounds were able to inhibit the growth of Gram positive and Gram negative
bacterial strains.
Maximum activity was observed in compound bearing R=4-chlorophenyl
and significant activity was displayed by compounds bearing R=phenyl, 4-
methoxyphenyl, 4-bromophenyl & 2,4-dimethylphenyl against Gram positive
bacterial strains B. cocous and B. subtillus. Other compounds were less active
against these bacterial strains.
In case of Gram negative bacterial strains highest activity was displayed by
compounds bearing R=phenyl and 3-nitrophenyl and significant activity was
observed in compounds bearing R=4-chlorophenyl and 2,5-dichlorophenyl
against E.coli & P. vulgaris.
ANTIFUNGAL ACTIVITY
Most of the compounds were inactive against fungal strain A. niger.
Maximum activity was observed in compounds bearing R=3-chloro, 4-
fluorophenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
Al l  the compounds displayed mi ld ant i tubercular  act iv i ty against
Mycobacterium tuberculosis H37Rv i.e. 1 to 39% inhibition.
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TABLE NO. 7a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
295622 HCV-116 C
6
H
5
- Alamar H
37
Rv >6.25 13 - MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295623 HCV-117 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 26 - "
295624 HCV-118 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 20 - "
295625 HCV-119 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 12 - "
295626 HCV-120 4-F-C
6
H
4
- Alamar H
37
Rv >6.25 18 - "
295627 HCV-121 3-Cl,4-F-C
6
H
3
- Alamar H
37
Rv >6.25 39 - "
295628 HCV-122 3-NO
2
- C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295629 HCV-123 2-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
295630 HCV-124 3/4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 1 - "
295631 HCV-125 4-Br-C
6
H
4
- Alamar H
37
Rv >6.25 20 - "
295632 HCV-126 2/4-(CH
3
)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 33 - "
295633 HCV-127 2/5-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 22 - "
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    PART-V
    STUDIES ON
     ISOXAZOLES
INTRODUCTION
Isoxazole derivatives have recently been intensively investigated. They are
interesting objects from the synthetic, as well as physiochemical, biological and
theoretical points of view.
Leflunomide (I) is an isoxazole derivative with antiinflammatory and
immunomodulating activity. It is also considered a prodrug, it is rapidlly
metabolized in vitro to its active metabolite A771726(II) via opening the
isoxazole ring. Most of the immunomodulating activity appears to be related to
A771726. It is also used for the management of the signs and symptoms of
rheumatoid arthritis and to retard structural damage associated with the disease
in adults with moderate to  active rheumatoid arthritis231-235.
SYNTHETIC ASPECTS
Isoxazoles may be prepared by the reaction between hydroxylamine and
α,β-dicarbonyl compounds. The reaction proceeds via the formation of oxime,
which possibly undergoes cyclization.
Isoxazoles can be prepared by various methods. They are described as under.
1. Fanshawe and Crawley236 prepared isoxazoles (IV) from chalcones,
hydroxylamine hydrochloride and KOH in methanol.
(I) (II)
O
N
H
CH3
O
NH CF3
F3C
NH
O CH3
OH
N
119
2. Lyubov N. Sobenina et. al.237 have synthsised isoxazole (V) by the reaction
of 2,2-dicyano-1-ethylthioethyl derivatives with hydroxylamine in methanol.
3. By the reaction of alkenes or alkynes with ammonium cerium (IV) nitrate in
acetone or acetophenone under reflux gave corresponding isoxazole
derivative238.
4. By the reaction of nitroalkanes with alkynes using microwave irradiation,
using 4-(4,6-dimethoxy[1,3,5]triazin-2-yl)-4-methylmorpholinium chloride
(DMTMM) and DMAP as catalyst239.
R
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THERAPEUTIC IMPORTANCE
Isoxazoles possess wide therapeutic activities.
1. Antiinflammatory240-242
2. Anticonvulsant243,244
3. Muscle relaxant245,246
4. Antipyretic247
5. Antibacterial248,249
6. Antiviral250
7. Anticholestermic251
8. Diabetic252
9. Herbicidal253
10. Antitumor254
11. Antileukemiac255
12. Nematocidal256
Masui et. al.257 have prepared isoxazoles having pesticidal activity. Some
excellent herbicidal results are obtained by Reddy et. al.258. Moreover isoxazoles
found to possess remarkable anxiolytic and antihypertensive effect, reported by
Nyitrai et. al.259. Aicher et. al.260 cited some isoxazole derivatives possessing
hypoglycemic agents. R. Ulrich et. al.261 have synthesised isoxazole derivatives
and reported their adrenergic antagonist activity.
Andres J I et. al.262 have discovered a new series of centrally active tricyclic
isoxazoles (IX) combining serotinin (5-HT)-reuptake inhibition with alpha(2)-
adreno-ceptor blocking activity which is described as potential antidepressant.
R1
NO2
DMTMM
DMAP, MeCN, MWI+ R2
N
OR1
R2
(VII)
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Hongwu He et. al.263 have prepared Methyl-1-(5-methyl-isoxazole-3-oxy-
acetoxy)alkyl-methyl phosphinates and tested for their plant growth regulatory
activity.
Chaumin, Wang, Yunfeng et. al.264 have discovered isoxazoles as herbicidal.
Wu, ahengde et. al.265 have synthesised isoxazole derivatives as endothelin
activity modulators. Corolin and co-workers266 have studied isoxazoles, which
have been used for the clinical trials of asthama.
Nanterment P G et. al.267 have discovered a non peptidic isoxazole
derivative (X) reported as antagonist of the human platelet thrombin receptor
(PAR1).
Romero J. R.268 has discovered a isoxazole derivative named pleconaril as
a antipicornaviral agent and promising drug for the treatment of enteroviral and
rhinoviral infections.
O
N
H
O
OMe
MeO
N
N CH3
(IX)
122
F
F
N O
N
N
OO(X)
Daniele Simoni and Manlio Tolomeo269 have designed a novel g1 phase
targetting isoxazole derivative (XI) which is structurally related to arotinoids, was
found to possess interesting apoptotic activity.
CONTRIBUTION FROM OUR LABORATORY
R. C. Khunt, A. R. Parikh and co-workers270 have prepared isoxazole
derivatives which possess antimicrobial activity. Rajeev Doshi & co-workers271
have discovered isoxazoles as a new class of potential antitubercular agents. Ketan
Hirpara et. al.272 have synthesised isoxazoles as antitubercular agents. A. V.
Dobaria et. al.273 have described the isoxazole derivatives and their use as
antimicrobial agents. B. P. Kansagar et. al.274 have demonstrated various isoxazole
and testd their antimicrobial activity.
Recently, Bo Lui et. al.275 have discovered novel isoxazole carboxamides
(XII) as growth hormone secretagogue receptor (GHS-R) antagonists. Patrizia Cali
et. al.276 have synthesised & reported isoxazoles (XIII) as peptide deformylase
inhibitors and potential antibacterial agent.
CH3CH3
CH3 CH3
CH3
O
N
HO2C
Cis form
(XI)
N
O
O
NH
CH3
R'
R
(XII) R, R' = Aryl/Alkyl (XIII)
N O
S R
O
NH
OH
R= Alkyl/Aryl
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Isoxazole derivatives (XIV) as a novel class of activators for chloride
conductance in the cystic fibrosis transmembrane conductance regulatorn  protein
has been identified by Robert Sammelson et. al.277. Wallace T. Ashton et. al.278
have found isoxazole (XV) as dipeptidyl peptidase IV inhibitors.
H. S. Yathirajan et.  al .279 have synthesised novel 4-(5-methyl-3-
phenylisoxazole-4-yl) benzene-sulfonamide ethylmethyl ketone (XVI) used as
non-sterodial intiinflammatory drug. Makarov V. A. and co-workers280 have
discovered the novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition
of human rhinovirus-2 and coxsackievirus B3 replication.
With an intension of preparing the compounds possessing better therapeutic
activity, we have undertaken the preparation of isoxazoles bearing pyrazole
moiety which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
ARYL-5 - [1 'N -PHENYL-3 ' -p -FLUOROPHENYL-
PYRAZOL-4'-YL]-ISOXAZOLES
(XIV) R1,R2= Alkyl
R3,R4= Alkyl/Aryl
(XVI)
N
O
CH3
S
O
O
NH2
1
2
CH3
O
CH3
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-ISOXAZOLES
With a view to getting better drug potency, isoxazole derivatives of type
(VIII) have been prepared by the condensation of chalcones of type (I) with
hydroxylamine hydrochloride in presence of sodium acetate in glacial acetic acid.
The chalcones were synthesised by the condensation of 1,N-phenyl-3-p-
fluorophenyl-4-formyl pyrazole with different aromatic ketones.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
R = ArylType - (VIII)
N
N F
N
O
R
N
N
F
O
R
NH2OH. HCl
CH3COONa
IR SPECTRAL STUDY OF 3-(p-ANISYL)-5-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-ISOXAZOLE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2923 2975–2920 426
–CH
3
C – H str. (sym.) 2852 2880–2840 "
C – H i.p. (def.) 1458 1470–1435 "
C – H o.o.p. (def.) 1357 1385–1350 "
Aromatic C – H str. (asym.) 3049 3080–3030 427
C = C str. 1542 1585–1450 "
C – H i.p. (def.) 1097 1125–1090 "
1028 1070–1000 "
C – H o.o.p. (def) 825 835–810 "
Pyrazole C = N str. 1618 1650–1600 428
moiety C – N str. 1334 1350–1200 "
C – F str. 756 760–710 "
Ether C – O – C str. (asym) 1222 1275–1200 "
C – O – C  str. (sym.) 1068 1075–1020 "
Isoxazole C = C str. 1506 1585–1450 426
C = N str. 1598 1650–1600 "
. N – O str. 842 850–800 "
N
N F
N
O
OCH3
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PMR SPECTRAL STUDY OF  3-(p-ANISYL)-5-[1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL]-ISOXAZOLES
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.84 3H singlet Ar-OCH
3
-
2. 6.92-6.94 2H doublet Ar-Hgg' Jgf=8.4
3. 7.06-7.12 2H triplet Ar-Hdd' -
4. 7.30-7.35 1H triplet Ar-Ha -
5. 7.42-7.50 4H multiplet Ar-Hbb'+Hee' -
6. 7.55-7.60 2H multiplet Ar-Hcc' -
7. 7.75-7.79 3H triplet Ar-Hff'+Hh Jfg = 10.6
8. 8.28 1H singlet CHx -
N
N F
N
O
OCH3
c
b
a
b'
c'
d e
e'd'
c
f
g
f'
g'
x
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EXPANDED AROMATIC REGION
N
N F
N
O
OCH3
c
b
a
b'
c'
d e
e'd'
c
f
g
f'
g'
x
N
N F
N
O
OCH3
m/z = 413 (m+2)
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-ISOXAZOLES
[A] Synthesis  o f  N-Aminophenyl - α -methyl - α -p - f luorophenyl -
azomethine
See, Part-I, Section-I (A)
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See, Part- I, Section-I (B).
[C] Synthsis of 1-(p-Anisyl)-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-
4'-yl)-2-propene-1-one
See, Part-I, Section-I (C).
[D] Synthesis of 3-(p-Anisyl)-5-[1',N-phenyl-3'-p-fluorophenyl pyrazol-
4'-yl]-isoxazoles
To a mixture of hydroxy amine hydrochloride (0.79, 0.01M) in ethanol and
anhydrous sodium acetate (0.82g, 0.01M) dissolved in minimum amount of hot
acetic acid was added a solution of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl)-2-propene-1-one (3.98g, 0.01M) in ethanol (15 ml). The contents
were refluxed on waterbath for 8 hrs. at temp 80o-90oC. The reaction product
was poured into ice and crystallised from ethanol. Yield 73%, m.p. 183oC;
(C25H18FN3O2; Found : C, 72.93%; H, 4.36%; N, 10.16%; Requires : C, 72.98%;
H, 4.41%; N, 10.21%).
Similarly other substituted isoxazoles have been prepared. The physical data
are recorded in Table No. 8.
[E] Therapeutic activity of 3-Aryl-5-[1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl]-isoxazoles
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No. 8.
Antitubercular  screening of the compounds of type(VIII) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-
I (D) and the percentage of inhibition data of the compounds are recorded in
Table No. 8a.
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TABLE NO. 8 : PHYSICAL CONSTANTS OF 3-ARYL-5-[1',N-PHENYL-3'-p-FLUOROPHENYL-PYRAZOL-4'-YL]-
ISOXAZOLES
Sr.
No.
1
8a C6H5- C24H16FN3O 381 98 0.56 70 11.02 10.96
8b 4-OCH3-C6H4- C25H18FN3O2 411 183 0.62 73 10.21 10.16
8c 4-CH3-C6H4- C25H18FN3O 395 105 0.55 69 10.63 10.56
8d 4-Cl-C6H4- C24H15ClFN3O 415 119 0.61 72 10.10 10.05
8e 4-F-C6H4- C24H15F2N3O 399 165 0.49 75 10.52 10.47
8f 4-OH-C6H4- C24H16FN3O2 397 147 0.58 62 10.57 10.51
8g 2-OH-C6H4- C24H16FN3O2 397 127 0.71 68 10.57 10.52
8h 4-NO2-C6H4- C24H15FN4O3 426 150 0.68 71 13.14 13.09
8i 3-NO2-C6H4- C24H15FN4O3 426 198 0.48 64 13.14 13.08
8j 4-Br-C6H4- C24H15BrFN3O 460 114 0.60 71 9.13 9.08
8k 4-NH2-C6H4- C24H17FN4O 396 162 0.74 64 14.13 14.07
8l C4H3S- C22H14FN3OS 387 159 0.46 67 10.85 10.81
*TLC Solvent System : Ethyl acetate : Hexane
2 : 8 (2a-2f, 2h-2j, 2l)
3 : 7 (2g, 2k)
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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GRAPHYCAL CHART NO.8: ANTIMICROBIAL ACTIVITY OF 3-ARYL-5-[1’N-PHENYL-3’-p- FLUOROPHENYL PYRAZOL-4’-YL]-ISOXAZOLES.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The activity data shows that isoxazoles (type-VIII) were able to inhibit the
growth of Gram positive & Gram negative bacterial strains.
Compounds bearing R=4-aminophenyl and 4-methylphenyl were observed
to give maximum activity against Gram positive bacterial strains B. subtillus
and B. cocous respectively as compared to standard drugs. Significant activity
was displayed by compounds containing R=4-methoxyphenyl, 4-hydroxyphenyl,
3-nitrophenyl and thienyl.
In case of Gram negative bacterial strains, maximum activity was observed
in compounds bearing 4-chlorophenyl and 4-fluorophenyl against P. vulgaris
and E. coli, significant activity was displayed by compounds bearing R=4-
methoxyphenyl and 4-bromophenyl.
ANTIFUNGAL ACTIVITY
Most of the compound were mild to moderately active against fungal strain
A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
A l l  t h e  c o m p o u n d s  d i s p l a y e d  ant i tubercu lar  a c t i v i t y  a g a i n s t
Mycobacterium tuberculosis H37Rv  ranging from 16 to 99% inhibition.
Compounds with R = 4-hydroxyphenyl, 2-hydroxyphenyl and 2-aminophenyl
exhibited maximum activity upto 99% inhibition.
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TABLE NO. 8a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
295574 HCV-68 C
6
H
5
- Alamar H
37
Rv >6.25 82 - MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295575 HCV-69 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 78 - "
295576 HCV-70 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 69 - "
295577 HCV-71 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 70 - "
295578 HCV-72 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 75 - "
295579 HCV-73 4-OH- C
6
H
4
- Alamar H
37
Rv <6.25 99 + "
295580 HCV-74 2-OH- C
6
H
4
- Alamar H
37
Rv <6.25 90 + "
295581 HCV-75 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 58 - "
295582 HCV-76 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 16 - "
295583 HCV-77 4-Br--C
6
H
4
- Alamar H
37
Rv >6.25 75 - "
295584 HCV-78 4-NH
2
-C
6
H
4
- Alamar H
37
Rv <6.25 99 + "
295585 HCV-79 C
4
H
3
S- Alamar H
37
Rv >6.25 70 - "
Corp
ID
Sample
ID
CommentAssay MTb
Strain
MIC
µg/ml
%
Inhib
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PART-VI
STUDIES ON
 CYANOPYRIDONES
INTRODUCTION
Pyridones, which belongs to an important group of heterocyclic compounds
have been extensively explored for their applications in the field of medicine.
Pyridones, with a carbonyl group at position 2(I) have been subject of extensive
study in recent past. Numerous reports have appeared in the literature which
highlight their chemistry and use.
2-Pyridones are derivatives of pyridine with carbonyl group at 2-position
(I). Someof the 2-pyridones are physiologically as well as pharmacologically
important which are as under. eg. amrinone (II), ciclopirox (III)and methylprylon
(IV).
SYNTHETIC ASPECTS
Different methods for preparation of 2-pyridones are as follows :
1. K. Folkers and S. A. Harris281 have synthsised 3-cyano-2-pyridones by the
condensation of cyanoacetamide with 1,3-diketone or 3-ketoester.
N
H
O
( I )
N
H
NH2
N
O N
H
O
O
C2H5
C2H5
CH3
( II ) ( III ) ( IV )
N O
CH3
OH
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2. Rajul Jain & co-workers282 have prepared 3-cyano-2-pyridones by reaction
of enones or enals with cyanoacetamide/BuOK in DMSO under O2
atmosphere.
3. M. A. Sluyter and co-workers283 have prepared fused 2-pyridones.
4. G. Simchen and G. Entemman284 have synthesised 2-pyridones in which
the ring nitrogen comes from a nitrile group in acyclic precursor.
THERAPEUTIC IMPORTANCE
Pyridone derivatives have been found to possess variety of therapeutic
activities as shown below.
1. Anticancer285
2. Herbicidal286
3. Pesticidal287,288
4. Antimicrobial289
5. Angitensin II antagonist290,291
6. Antiviral292
7. AntiHIV293
Salman A S 294 has prepared cyano pyridone derivatives as antibacterial &
antifungal agent. Thomas C J et. al.295 and M. Potmesil & H. Pinedo296 have
prepared 2-pyridone derivatives (V) as antineoplastics, antitumor & antiviral agent.
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R1,R2,R3= Alkyl
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Peter and co-workers297 have prepared pyridinylmethyl substituted pyridines
and pyridones as angitensin II antagonist. H. Posnes298 has synthesised 2-
pyridones and 2-pyrones as physiologically active compounds. Mukhtar Hussain
Khan and co-workers299,300 have prepared 2-pyridone derivatives (VI) and (VII)
which possess insecticidal and pesticidal activity.
Morishita Koji et. al.301 have synthesised m-(2-oxo-1,2-dihydropyridyl) urea
derivatives (VIII) possessing cholesterol acyltransterase (ACAT) inhibitory activity
and are useful for the treatment of hyperlipidemia and arteriosclerosis.
N
N
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( V )
R1=R2=H=Campthothecin
R1=CH2NMe2, R2=OH=Topotecan
( VI ) ( VII )
N
H
N
S
O
N
R
S
R1
NH
N
H
N
N
O
R
O
R1
R, R1 = Aryl
N
O
CH3
O
N
H
O
Bu
N
H
Pr
Pr
( VIII )
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Collins et. al.302 have prepared heteroaryl pyridones as GABA α2/α3 ligands.
Pednekar303 synthesised fused 2-pyridone derivatives (IX), (X) and (XI) as useful
heterocyclic moieties as they possess broad spectrum of biological activities such
as antiviral, CNS depressant, bactericidal and ulcer inhibitor.
Moreover, several co-workers have prepared 2-pyridones as S3 site of
thrombin inhibitor304, herbicidal305, SH2 domain inhibitor306, antimicrobial307,
GABA-A receptor308 and antiinflammatory309.
Upadhyay and co-workers310 have synthesised cyanopyridone derivatives
which showed antifungal and antileishmanial activities. E. Amer311 has prepared
3-cyano-2-pyridone derivatives (XII) displaying high antimicrobial activity. Abou
El-Fotooh and co-workers312 have demonstrated pyridones (XIII) as anticancer
agent.
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X = F, Cl, Br
M. G. Nizamuddin et. al.313 have prepared cyanopyridone derivatives (XIV)
and documented their antifungal activity.
Recently, Tanaka Akira et. al.314 have prepared pyrazolo pyridone
derivatives (XV). Haifeng Song & co-workers315 have synthsised 3-cyano
pyridones (XVI) which are used as dyes and pigment.
Darcy Michael G. et. al.316 have discovered pyridones as antiviral agents.
Smith Terence317 has synthesised and reported pyridones (XVII) as AMPA receptor
antagonists for the treatment of demyelinating disorders and neurodenerative
diseases. Recently, it is found that pyridones possess antiallergic318, p38 MAP
Kinase319 & modulating, thrombin inhibitor320 activities.
N
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( XIV ) R & R1 = Aryl
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With an intension of preparing the compounds possessing better therapeutic
activity, we have undertaken the preparation of cyanopyridones which have been
described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-
CYANO-4-[1' ,N-PHENYL-3'-p-FLUOROPHENYL-
P Y R A Z O L - 4 ' -Y L ] - 6 -A R Y L - 1 , 2 -D I H Y D R O - 2 -
PYRIDONES
N N
O
N
( XVII )
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-[1',N-
PHENYL-3 ' -p -FLUOROPHENYL PYRAZOL-4 ' -YL] -6-ARYL-1,2-
DIHYDRO-2-PYRIDONES
Pyridone derivatives possess interesting therapeutic activity. Taking this into
consideration, we have undertaken the preparation of  pyridone derivatives by
the condensation of chalcones of type (I) with ethyl cyanoacetate in presence of
ammonium acetate as shown under.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of synthesised compounds were compared with standard
drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
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IR SPECTRAL STUDY OF 3-CYANO-4-(1',N-PHENYL-3'-p-FLUOROPHENYL-PYRAZOL-
4'-YL)-6-(p-ANISYL)-1,2-DIHYDRO-2-PYRIDONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2922 2975–2920 426
–CH
3
C – H str. (sym.) 2852 2880–2820 "
C – H i.p. (def.) 1454 1470–1435 "
C – H o.o.p. (def.) 1338 1385–1350 "
Aromatic C – H str. 3057 3080–3030 427
C – H i.p. (def.) 1099 1125–1090 "
1014 1070–1000 "
C – H o.o.p. (def.) 837 835–810 "
Pyrazole C = N str. 1596 1650–1590 428
moety C = C str. 1504 1585–1480 "
C – N str. 1236 1350–1200 "
C – F str. 750 760–700 "
Ether C – O – C str. (asym) 1236 1275–1200 "
C – O – C str. (sym.) 1072 1075–1020 "
Pyridone C ≡ N str. 2218 2240–2120 432
ring C = O str. 1649 1760–1655 "
N – H str. 3417 3450–3250 "
N
N
F
NH
O
N
OCH3
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PMR SPECTRAL STUDY OF  3-CYANO-4-[1'N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL]-6-(p-ANISYL)1,2-DIHYDRO-2-PYRIDONE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.84 3H singlet Ar-OCH
3
-
2. 6.20 1H singlet Ar-Hh -
3. 6.90-6.93 2H doublet Ar-Hgg' Jgf=8.7
4. 7.11-7.17 2H triplet Ar-Hdd' -
5. 7.38-7.43 3H triplet Ar-Hbb' + Ha -
6. 7.51-7.54 2H doublet Ar-Hee' Jed= 7.8
7. 7.60-7.64 2H multiplet Ar-Hcc' -
8. 7.80-7.82 2H doublet Ar-Hff' Jig=8.1
9. 8.57 1H singlet CHx -
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-CYANO-4-(1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-6-ARYL 1,2-DIHYDRO-
2-PYRIDONES
[A] Synthesis  o f  N-Aminophenyl - α -methyl -2-p-f luorophenyl -
azomethine
See, Part-I, Section-I (A)
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See, Part- I, Section-I (B).
[C] Synthesis of 1-(p-Anisyl)-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-
4'-yl)-2-propene-1-one
See, Part-I, Section-I (C).
[D] Synthesis of 3-cyano-4-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-
yl)-6-(p-anisyl)-2-pyridone
A mixture of 1-(p-anisyl)-3-(1',N-phenyl-3'-p-flurophenyl-pyrazol-4'-yl)-2-
propene-1-one (3.98g, 0.01M) ethyl cyano acetate (1.13g, 0.01M) and ammonium
acetate (5.92g, 0.08M) in absolute alcohol was refluxed for 10 hrs. at temp 70o-
80oC. The reaction product was poured into ice, filtered and crystallised from
ethanol. Yield 68% m.p.> 300oC (C28H19FN4O2 : Found : C, 72.63%; H,
4.07%; N, 12.02%; Requires : C, 72.72%; H, 4.14%; N, 12.11%).
Similarly other substituted pyridones have been prepared. The physical data
are recorded in Table No. 9.
[E] Therapeutic activity of 3-Cyano-4-(1',N-phenyl-3'-p-fluorophenyl-
pyrazol-4'-yl)-6-aryl-pyridones
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No. 9.
Antitubercular  screening of the compounds of type(IX) were carried out by
TAACF, the Southern Research Institute, U.S.A. as described In Part-I, Section-I
(D) and the percentage of inhibition data of the compounds are recorded in Table
No. 9a.
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TABLE NO. 9 : PHYSICAL CONSTANTS OF 3-CYANO-4-[1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-
6-ARYL-1,2-DIHYDRO-2-PYRIDONES
Sr.
No.
1
9a C6H5- C27H17FN4O 432 117 0.41 61 12.96 12.86
9b 4-OCH3-C6H4- C28H19FN4O2 462 >300 0.52 68 12.11 12.02
9c 4-CH3-C6H4- C28H19FN4O 446 102 0.63 60 12.55 12.47
9d 4-Cl-C6H4- C27H16ClFN4O 466 202 0.47 68 12.00 11.94
9e 4-F-C6H4- C27H16F2N4O 450 122 0.46 64 12.44 12.38
9f 4-OH-C6H4- C27H17FN4O2 448 192 0.72 72 12.49 12.40
9g 2-OH-C6H4- C27H17FN4O2 448 162 0.60 65 12.49 12.38
9h 4-NO2-C6H4- C27H16FN5O3 477 138 0.56 62 14.67 14.61
9i 3-NO2-C6H4- C27H16FN5O3 477 182 0.75 74 16.67 14.59
9j 4-Br-C6H4- C27H16BrFN4O 511 232 0.48 71 10.96 10.88
9k 4-NH2-C6H4- C27H18FN5O 447 131 0.51 64 15.65 15.57
9l C4H3S- C25H15FN4O5 438 112 0.66 67 12.78 12.70
*TLC Solvent System : Acetone : Benzene
2 : 8
Rf*
Value
6
Yield
%
7
Molecular
Formula
3
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GRAPHYCAL CHART NO.9: ANTIMICROBIAL ACTIVITY OF 3-CYANO-4-[1’N-PHENYL-3’-p- FLUOROPHENYL PYRAZOL-4’-YL]
-6-ARYL-1,2-DIHYDRO-2-PYRIDONES.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the activity data, it has been concluded that the pyridone (type-IX)
derivatives were able to inhibit the growth of Gram positive and Gram negative
bacterial strians.
Maximum activity was observed in compounds bearing R=4-hydroxyphenyl
& 4-aminophenyl against  Gram posi t ive bacter ial  s trains,  B. cocous &
B. subtillus. Significant activity was observed in compounds bearing R=4-
chlorophenyl, 4-bromophenyl, 4-f luorophenyl, 4-methoxyphenyl and 3-
nitrophenyl against Gram positive bacterial strains B. cocous & B. subtillus.
In case of Gram negative bacterial strains, maximum activity was observed
in compounds bearing R=4-methoxyphenyl and 4-nitrophenyl, while other
compounds were mild to moderately activity.
ANTIFUNGAL ACTIVITY
In case of fungal strain A. niger, maximum activity was observed in
compound bearing R=4-bromophenyl. All the others compounds were mild to
moderately active.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
Al l  the  compounds  d i sp layed ant i tubercu lar  ac t iv i ty  aga ins t
Mycobacterium tuberculosis H37Rv ranging from 5 to 83% inhibition.
Compounds with R = thienyl showed maximum activity i.e. 83% inhibition.
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TABLE NO. 9a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
N
N
F
NH
R
O
N
Corp
ID
Sample
ID
CommentAssay MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
295562 HCV-56 C
6
H
5
- Alamar H
37
Rv >6.25 60 - MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295563 HCV-57 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 34 - "
295564 HCV-58 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 41 - "
295565 HCV-59 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 34 - "
295566 HCV-60 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 34 - "
295567 HCV-61 4-OH- C
6
H
4
- Alamar H
37
Rv >6.25 37 - "
295568 HCV-62 2-OH- C
6
H
4
- Alamar H
37
Rv >6.25 12 - "
295569 HCV-63 4-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295570 HCV-64 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 5 - "
295571 HCV-65 4-Br--C
6
H
4
- Alamar H
37
Rv >6.25 46 - "
295572 HCV-66 4-NH
2
-C
6
H
4
- Alamar H
37
Rv >6.25 53 - "
295573 HCV-67 C
4
H
3
S- Alamar H
37
Rv >6.25 83 - "
PART-VII
STUDIES ON
        IMIDAZOLINONES
INTRODUCTION
Imidazolinone, a five membered heterocycle having 2-nitrogen atoms at
the 1 and 3-positions and C=O group at following positions : 2-oxo-imidazoline
(I), 4-oxo-imidazoline (II), 5-oxo-imidazoline (III).
The discovery of the 2-substituted-5-imidazolines dates back to the year
1888, when A. W. Hoffman321 for the first time discovered 5-oxo-imidazoline by
heating N'-diacetylethylene diamine in a stream of dry hydrogen chloride.
Moreover the same compound was prepared by A. Ladenburg322 by the fusion
of two equivalents of sodium acetate with one equivalent of ethylene diamine
dihydrochloride.
SYNTHETIC ASPECTS
Various methods have been reported for the synthesis of imidazolinones in
literature323 are as under.
1. Aminolys is  of  oxazolone wi th amine leads to the format ion of
imidazolinones324.
2. A. Saxena et. al.325 have synthesised new imidazolinones in pyridine.
3. Allimony et. al.326 have synthesised new imidazolinone derivatives by
conventional method.
4. Feng-Jun-Cai et. al.327 have synthesised 5-imidazolinone derivatives by
microwave irradiation.
(III)(II)(I)
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N
H
O
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O
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O
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MECHANISM
Azalactone reacts with variety of compounds such as water, alcohols, amines
and hydrogen halides. Amides of α-acylamino acrylic acids obtained from the
condensat ion of  aza lac tone and pr imary amine can be conver ted to
imidazolinones as shown under.
The ring closer can be effected under a variety of conditions. Substituted
anilides have been converted to imidazolinone derivatives by the action of POCl3.
THERAPEUTIC IMPORTANCE
Naphazoline hydrochloride, xylometazoline hydrochloride etc are various
imidazolinone derivatives which have been used as adrenergic stimulants and
tolazol ine and phenotolamine as adrenergic b locking agents .  Var ious
imidazolinones are known to exhibit a broad spectrum of biological activities
such as,
1. Antitubercular328
2. Potent CNS depressant329
3. Antiviral330
4. Antihypertensive331
5. Antiinflammatory332
6. Antimicrobial333
7. Anticonvulsant334
8. Fungicidal335
9. Anticancer336
10. Antidiabetic337
R2-NH2
O
N
O
R
R1
NH
O
R
R1
O
NH R2
POCl3
N
N
O
R
R1
R2
Dry C5H5N / Abs. C2H5OH, K2CO3
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Prisinzano T. et. al.338 have synthesised & reported imidazoline derivatives
as human 5-HT(1D) serotonin receptor ligands. Zhong Jin339 has found imizoline
derivatives (IV) as cytoxic towards several tumor cell lines. Moutevelis-Minakakis
P. et. al.340 have synthesised imidazolines as antihypertensive agent. Katarzyna
Kiee-Knonowicz et. al.341 have discovered imidazolinones  as antimicrobial
agents. Solankee A. et. al.342 have prepared imidazolinones (V) as anticancer
agents.
Havera Herbert J & co-workers343 have synthesised imidazolinones as
antiarrhythmic agents. Some androgenic inhibitor and estrogen activities of
imidazoline derivatives have been found by Saad Samir F.344.
Christopher Geoffrey et. al.345 have synthesised imidazolinones and reported
their antifungal activities. T. Okasaki et. al.346 have discovered imidazolinone
derivatives as angiotensine II receptor antagonist (VI). Kallurava B. et. al.347 have
reported antibacterial, antiinflammatory and analgesic activity of 5-oxo-
imidazoline derivatives.
NH
N
N
NH3CO
OCH3
OCH3N
O
CH3
O
(IV)
N
N
Ph
N
N
Me
Me
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(V)
N N
N
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CH3
R = (Me, Et)(VI)
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CONTRIBUTION FROM OUR LABORATORY
Dr. H. H. Parekh et. al.348 have suggested imidazolinones as antitubercular
and anticancer (VII) agents.
H. H. Parekh and co-workers349 have synthesised 5-oxo-imidazolines as
novel bioactive compounds derived from benzimidazole. P. H. Patel and co-
workers350 have discovered imidazolines bearing 2-amino-thiazole moiety as
antimicrobial agents. R. C. Khunt, N. J. Datta and A. R. Parikh351 have reported
5-oxo-imidazolines as biologically active agents. Hasmukh Kanjaria and co-
workers352 have described imidazolinones as potential antimicrobial agents.
Satyan P. Patel and co-workers353 have synthesis imidazolines as biologically
active agents.
Joshi H. et. al.354 have synthesised imidazolinones as potent anticonvulsant
agents. Parikh et. al.355 have repor ted 4-(4'-arylidene-2'-phenyl-5'-oxo-
imidazolin-1'-yl)-benzophenone and screened for their antimicrobial activity.
Recently, it is found that imidazolinones possess anticancer356 (VIII),
antibacterial357 (IX) and antimicrobial358 activities.  Coleman P. et. al.359 have
demonstrated imidazole derivatives as immune response modifiers. Essar Franz
et. al.360 have screened imidazolidines for treatment of urinary incontinence.
O
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With a view to getting better therapeutic agent, it was contemplated to
synthesise imidazolinones to enhance the overall drug potential of resulting
compounds which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1,N-ARYL-2-ALKYL/ARYL-4-(1' ,N-PHENYL-3'-p-
FLUOROPHENYL -4 ' -PYRAZOLYLMETHINO) -
IMIDAZOLIN-5-ONES.
N
N
N N
O
Ar2Ar1
Ar1, Ar2 = Aryl
(VIII) (IX)
N
N
H N N
N
Ph
OH
Et
S
Ph
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4 - (1 ' ,N -PHENYL-3 ' -p -FLUOROPHENYL-4 ' -PYRAZOLYL-
METHINO)-IMIDAZOLIN-5-ONES
Imidazolinones represent one of the most active classes of compounds having
a wide spectrum of biological activities with an aim to getting better therapeutic
agent. The preparation of 5-oxo-imidazolines of type (X) have been undeartaken
by the condensation of azalatone with different aromatic amines as shown in
reaction scheme.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and further supported by mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with
standard drugs.
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Type - (X)
R1 = Alkyl / Aryl
R2 = Aryl
REACTION SCHEME
Type - (X)
R1 = Alkyl / Aryl
R2 = Aryl
N
N
F
O
N
R1
O
R2 - NH2
Pyridine
N
N
F
N
N
O
R2 R1
(CH3CO)2O
CH3COONa
N
N
CHO
F
+
O
NH
HOOC
R1
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IR SPECTRAL STUDY OF 1,N-p-TOLYL-2-PHENYL-4- (1 ' ,N-PHENYL-3 ' -p -
FLUOROPHENYL-4'-PYRAZOL METHINE)-IMIDAZOLIN-5-ONE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2918 2975–2920 426
–CH
3
C – H str. (sym.) 2854 2880–2860 "
C – H i.p. (def.) 1446 1470–1435 "
C – H o.o.p. (def.) 1363 1395–1370 "
Aromatic C – H str. 3031 3090–3020 427
C = C str. 1502 1585–1480 "
C – H i.p. (def.) 1109 1125–1090 "
1068 1070–1000 "
C – H.o.o.p (def.) 821 840–810 "
Pyrazole C = N str. 1600 1650–1590 428
moety C = C str. 1502 1585–1480 "
C – F 758 760–700 "
Imidazolinone C = O str. 1708 1760–1655 426
ring C = N str. 1637 1650–1580 "
C – N – C str. 1145 1160–1130 "
N
N
F
N
N
O
CH3
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PMR SPECTRAL STUDY OF  1,N-TOLYL-2-PHENYL-4- [1 ' ,N-PHENYL,3 ' -p-
FLUOROPHENYL-PYRAZOL-4'-YL-METHINO]-IMIDAZOLIN-5-ONES
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1 2.29 3H singlet Ar-CH3 -
2. 7.07-7.09 2H doublet Ar-Hgg'
3. 7.18-7.21 2H triplet Ar-Hee' Jef=7.6
4. 7.23-7.29 1H triplet Ar-Ha -
5. 7.32-7.42 3H quarlet Ar-Hbb'+Hh -
6. 7.50-7.62 6H multiplet Ar-Hii'+jj'+dd' -
7. 7.73-7.77 2H triplet Ar-Hcc' _-
8. 8.13-8.16 2H doublet Ar-Hff' Jfe=6.9
9. 8.45 1H singlet CHx -
10. 9.74 1H singlet CHk -
N
N
F
N
N
O
CH3
c
b
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c'
d e
e'
d'
k
j'
i'
h
i
jf'
g'
g
f
159
EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ARYL-2-ALKYL/
ARYL-4-(1',N-PHENYL-3'-p-FLUOROPHENYLMETHINO)-IMIDAZOLIN-
5-ONES
[A] Synthesis of 1,N-phenyl-3-p-fluorophenyl-4-formyl pyrazole
See, Part-I, Section-I (B).
[B] Synthesis of 2-phenyl-4-(1',N-phenyl-3'-p-fluorophenyl-4'-pyrazolyl
methino)-oxazolin-5-one
A mixture of 1,N-phenyl-3-p-fluorophenyl-4-formyl pyrazole (2.65gm,
0.01M), acetic anhydride (2.5 ml, 0.025 M) sodium acetate (1.2 gm 0.015M)
and hippuric acid (2.59g, 0.015M) was heated on a water bath for 4 hrs. Resulting
mass wass poured into ice cold water, filtered and crystallised from MeoH. Yield,
67%, m.p. 144oC,   (C25H16FN3O2 ; Found : C, 73.26%; H, 3.88%; N, 10.17%;
Requires : C, 73.34%; H, 3.94%; N, 10.26%).
[C] Synthesis of 1,N-Tolyl-2-phenyl-4-(1',N-phenyl-3'-p-fluorophenyl-4'-
pyrazolylmethino)-imidazoline-5-one
A mix ture  o f  2-pheny l -4- (1 ' ,N-pheny l -3 ' -p- f luoropheny l -4 ' -
pyrazolylmethino)-oxazolin-5-one (4.08g, 0.01M) and toludine (1.07g, 0.01M)
in dry pyridine (20 ml) was refluxed for 9 hrs. at temp. 140oC in oil bath. temp
Resulting mass was poured into crushed ice and neutralised with HCl, filtered
and crystallized from DMF. Yield, 67%; m.p. 244oC, (C32H23FN4O : Found : C
78.96%; H, 6.57%; N, 11.14%; Required : C, 77.09%; H, 4.65%; N, 11.24%).
Similarly, other imidazolin-5-ones have been prepared. The physical
constants are recorded in Table No. 10.
[D] Antimicrobial activity of 1,N-Aryl-2-alkyl/aryl-4-(1',N-phenyl-3'-p-
fluorophenyl-4'-pyrazolylmethino)-imidazolin-5-ones
Antimicrobial activity was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.10.
161
Molecular
Formula
4
R
1
2
TABLE NO. 10 : PHYSICAL CONSTANTS OF 1,N-ARYL-2-ALKYL/ARYL-4-(1',N-PHENYL-3'-p-FLUOROPHENYL-4'-
PYRAZOLYLMETHINO)-IMIDAZOLIN-5-ONES
Sr.
No.
1
10a C6H5- C6H5 C31H21FN4O 484.5 232 0.62 68 11.56 11.48
10b C6H5- 4-OCH3-C6H4- C32H23FN4O2 514.5 221 0.58 55 10.89 10.81
10c C6H5- 4-CH3-C6H4- C32H23FN4O 498.5 244 0.61 67 11.24 11.14
10d C6H5- 4-Cl-C6H4- C31H20ClFN4O 518.9 205 0.57 63 10.80 10.72
10e C6H5- 3-Cl-C6H4- C31H20ClFN4O 518.9 228 0.55 68 10.80 10.71
10f C6H5- 4-F-C6H4- C31H20F2N4O 502.5 195 0.51 57 11.15 11.07
10g C6H5- 2-F-C6H4- C31H20F2N4O 502.5 219 0.47 71 11.15 11.05
10h C6H5- 3,4-(Cl)2-C6H3- C31H19Cl2FN4O 553.4 179 0.56 65 10.12 10.03
10i C6H5- 3-Cl,4-F,C6H3- C31H19ClF2N4O 536.9 188 0.49 58 10.43 10.32
10j C6H5- 2,4-(CH3)2-C6H3- C33H25FN4O 512.5 213 0.59 66 10.93 10.83
10k C6H5- 4-Br-C6H4- C31H20BrFN4O 563.4 209 0.64 59 9.94 9.87
10l C6H5- 4-NO2-C6H4- C31H20FN5O3 529.5 237 0.50 60 13.23 13.15
*TLC Solvent System : Ethyl acetate : Hexane
1.5 : 8.5
% of Nitrogen
Calcd.
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Found
10
Yield
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GRAPHYCAL CHART NO.10: ANTIMICROBIAL ACTIVITY OF 1,N-ARYL-2-ALKYL/ARYL-4-[1’N- PHENYL-3’-p-FLUOROPHENYL PYRAZOL-4’-YL]
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The activity data shows that all the imidazolinones (type-X) were able to
inhibit the growth of Gram positive & Gram negative bacterial strains.
Compounds  bear ing  R=4-methypheny l  4-bromopheny l  & 2 ,4-
dimethylphenyl were observed to give the promising activity against Gram
positive bacterial strains B. cocous & B. subtillus respectively, as compared
to standard drugs. Significant activity was displayed by compounds bearing R=4-
methoxyphenyl, 2-fluorophenyl, 4-chlorophenyl and 4-nitrophenyl.
In case of Gram negative bacterial strains, maximum activity was observed
in compounds bearing R=4-fluorophenyl and 3-nitrophenyl against E. coli and
P. vulgaris. Significant activity was displayed by compounds bearing R=2-
fluorophenyl and 3,4-dichlorophenyl against these Gram negative bacterial
strains.
ANTIFUNGAL ACTIVITY
All the compounds were mild to moderately active against fungal strain
A. niger .  Maximum activty was observed in compound bearing R=4-
bromophenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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  PART-VIII
  STUDIES ON
                   NITRILES
INTRODUCTION
Nitriles are reported to possess various therapeutic activities, but due to
their high toxicity, they have low therapeutic importance. The term "Nitrile" was
first introduced by Febung361 in 1844. The first synthesis of nitrile has been
reported by Wohler and Liebig362 in 1832 and Poleuze363 in 1834. They are
very much useful as intermediates for various products such as acrylonitrile for
plastic, synthetic rubber and fibers, phthalonitrile for dye stuff.
SYNTHETIC ASPECTS
D. Mowry364 reviewed various methods of preparation of nitrile. Few recent
methods are as mentioned below.
1. From alkylhalides using KCN tetraalkyl ammonium salt365 and water in trace.
2. The pyrolysis of schiff's base366
3. MOhanakrishna A. K. and co-worker367 have synthesised nitrile derivatives
MECHANISM
The mechanism of nitrle is shown as under.
O
H
R
+ CN
OH
CN
R
OH
CN
H
R
R1-NH2
-H2O
NH
CN
H
R
R1
H+
:
:
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THERAPEUTIC EVALUATION
They shows various therapeutic activities, which are described as under.
1. Antihypertensive368
2. Central nervous system agent369
3. Antimicrobial370
4. Antihypoxic371
5. Antiinflammatory372
6. Antiarrytheymic373
7. Pesticidal374
8. Fungicidal375
Kobayashi Shigco et. al.376 have synthesised new derivatives of nitriles.
Nitriles with fused pyridine ring were reported as ulcer inhibitors377. Cardenalide
nitrile showed moderate biological activity in rats378. M. C. Dougal379 have
synthesised nitriles and studied their pharmacological activities.
Parlo Sanna et. al.380 have synthesised nitriles(I) and screened for their
antitubercular activity. Iwanowicz E. J. et. al.381 have prepared nitriles (II) and
found to preventing and treating IMPDH associated disorders, such as transplant
rejection and autoimmune disease.
V. Juliya et. al.382 synthesised some new nitriles and reported them as
anticonvulsant agent. Shibata Yasushi and co-workers383 have synthesised nitrile
derivatives associated with  insecticidal activity. Nosyrava et. al.384 have prepared
novel nitriles which have been shown to possess muscle relaxant activity. Yagihara
and co-workers385 have prepared nitrile which possess antimicrobial and
antiinflammatory activity.
N
N
N
NH2
N
N N
N
NH2
S
CH3
N
(II)(I)
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Altmann Eva et. al.386 have discovered dipeptide nitriles as inhibitors of
cysteine cathepsins. Shibata Yasushi et. al.387 have synthesised and reported nitrile
derivatives as insectisides and miticides.
Recently, Colin Xavier and co-workers388 have synthesised antifungal
acetonitriles. Bernard M. et. al.389 have prepared nitriles as thromboxane receptor
antagonists. Alwal K. S. et. al390 have prepared nitri les as inhibitors of
mitochondrial F1F10 AT pase. Murakkami Hiroshi et. al.
391 have synthesised some
new nitriles and screened for their pesticidal and marine antifouling activity.
CONTRIBUTION FROM OUR LABORATORY
F. M. Bharmal et. al.392 have synthesised newer acetonitriles bearing
quinoline moiety and tested as antimicrobial agents (III).
Looking to the interesting properties of nitriles, we have synthesised some
new nitriles, which have been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF α-
ARYLAMINO-1,N-PHENYL-3-p-FLUOROPHENYL-
PYRAZOL-4-YL-ACETONITRILES
(III)
N Cl
N
NH
R
CH3
R = Aryl
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-1,N-
PHENYL-3-p-FLUOROPHENYL PYRAZOL-4-YL-ACETONITRILES
In view of the therapeutic activities of nitriles it was contemplated to
synthesise some new nitriles in search of agents possessing higher biological
activity. Nitrles of type (XI) have been synthesised by the reaction of 1,N-phenyl-
3-p-fluorophenyl-4-formyl-pyrazole with different aromatic amines by the
presence of sodium cyanide and glacial acetic acid at 0-5oC.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antimicrobial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with
standard drugs.
The synthesised compounds have been screened for their in vitro biological
assay like antitubercular activity towards a strain of Mycobacterium tuberculosis
H37Rv at concentration of 6.25 µg/ml using Rifampin as standard drug.
N
N
CHO
F
R2 - NH2, NaCN
0-5 C, gl. CH3COOH
o
N
N
F
NH
R
N
R = ArylType - (XI)
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IR SPECTRAL STUDY OF α-(p-ANISYLAMINO)-1,N-PHENYL-3-p-FLUOROPHENYL-
PYRAZOL-4-YL-ACETONITRILE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2920 2975–2920 426
–CH
3
C – H str. (sym.) 2866 2880–2860 "
C – H i.p. (def.) 1454 1470–1435 "
C – H o.o.p. (def.) 1357 1395–1370 "
Aromatic C – H str. 3033 3090–3030 427
C = C str. 1554 1520–1480 "
C – H i.p. (def.) 1126 1125–1090 "
1062 1070–1000 "
C – H.o.o.p (def.) 815 835–810 "
Pyrazole C = N str. 1600 1610–1590 428
moety C – N str. 1217 1230–1220 "
C = C str. 1515 1585–1480 "
C – F 759 760–710 "
Nitrile C ≡ N str. 2237 2240–2220 432
N – H str. (sym.) 3332 3450–3200 "
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PMR SPECTRAL STUDY OF  α-(p-ANISYLAMINO)-1,N-PHENYL-3-p-FLUOROPHENYL-
PYRAZOL-4-YL ACETONITRILE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 3.79 3H singlet Ar-OCH
3
-
2. 5.28 1H singlet CHh -
3. 6.77-6.80 2H doublet Ar-Hgg' Jgf=8.7
4. 6.87-6.90 2H doublet Ar-Hdd' Jde=9
5. 7.09-7.14 2H triplet Ar-Hbb' -
6. 7.33-7.36 1H triplet Ar-Ha -
7. 7.47-7.52 2H triplet Ar-Hee' -
8. 7.74-7.83 4H multiplet Ar-Hff' + Hcc' -
9. 8.30 1H singlet CHx -
N
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF α-ARYLAMINO-1,N-
PHENYL-3-p-FLUOROPHENYL-PYRAZOL-4-YL-ACETONITRILES
[A] Synthesis  of  N-Phenylamino- α -methyl - α -p - f luorophenyl -
azomethine
See, Part-I, Section-I (B).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl-pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of α-(p-Anisylamino)-1,N-phenyl-3-p-fluorophenyl-
pyrazol-4-yl-acetonitrile
1,N-Phenyl-3-p-fluorophenyl-4-formyl-pyrazole (2.65g, 0.01M) dissolved
in ethanol (20 ml) was added to sodium cyanide (0.48g, 0.01M) dissolved in
water (5 ml) followed by glacial acetic acetic acid (5 ml). The contents were then
stirred for 5 minutes to form cyanohydrin at 0oC. p-Anisidine (1.23g, 0.01M)
dissolved in methanol was added to the reaction mixture, contents were kept at
room temp. for 24 hrs. and poured into ice. The solid product was crystallized
from DMF. Yield, 70%, m.p. 199oC (C24H19FN4O ; Found : C, 72.28%; H, 4.74%;
N, 13.98%; Requires : C, 72.35%; H, 4.81%; N, 14.06%).
Similarly, other nitriles were prepared. The physical constants are recorded
in Table No. 11.
[D] Therapeutic activity of α-Arylamino-1, N-phenyl-3-p-fluorophenyl-
pyrazole-4-yl-acetonitriles
Antimicrobial testing was carried out as described in Part-I, Section-I (D).
The zone of inhibition of the test solution are recorded in Graphical Chart No.
11.
Antitubercular  screening of the compounds of type(XI) were carried out
by TAACF, the Southern Research Institute, U.S.A. as described In Part-I,
Section-I (D) and the percentage of inhibition data of the compounds are
recorded in Table No. 11a.
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TABLE NO.11 : PHYSICAL CONSTANTS OF α-ARYLAMINO-1,N-PHENYL-p-FLUOROPHENYL PYRAZOL-4-YL-
ACETONITRILES
Sr.
No.
1
11a C6H5- C23H17FN4 368.4 167 0.48 64 15.21 15.16
11b 4-OCH3-C6H4- C24H19FN4O 398.4 199 0.47 70 14.06 13.98
11c 4-CH3-C6H4- C24H19FN4 382.4 141 0.50 62 14.65 14.57
11d 2-CH3-C6H4- C24H19FN4 382.4 172 0.52 58 16.65 16.56
11e 4-Cl-C6H4- C23H16ClFN4 402.8 189 0.57 71 13.91 13.85
11f 3-Cl-C6H4- C23H26ClFN4 402.8 177 0.60 67 13.91 13.83
11g 4-F-C6H4- C23H16F2N4 386.3 154 0.63 61 14.50 14.42
11h 3,4-(Cl)2-C6H3- C23H15Cl2FN4 437.2 180 0.65 68 12.81 12.76
11i 2,3-(Cl)2-C6H3- C23H15Cl2FN4 437.2 193 0.53 63 12.81 12.73
11j 3-Cl,4-F-C6H3- C23H15ClF2N4 420.8 202 0.56 59 13.31 13.24
11k 3-NO2-C6H4- C23H16FN5O2 413.4 162 0.55 69 16.94 16.87
11l 4-Br-C6H4- C23H18BrFN4 447.3 175 0.49 67 12.53 12.45
*TLC Solvent System : Acetone : Benzene
1.8 : 8.2
Rf*
Value
6
Yield
%
7
Molecular
Formula
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GRAPHYCAL CHART NO.11: ANTIMICROBIAL ACTIVITY OF a-ARYLAMINO-1,N-PHENYL-3-p- FLUOROPHENYL PYRAZOL-4-YL
-ACETONITRILES.
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CONCLUSION
ANTIBACTERIAL ACTIVITY
The antibacterial activity of acetonitriles (type-XI) revealed that many
compounds were able to inhibit the growth of Gram positive and Gram negative
bacterial strains.
Maximum activity was observed in compounds bearing R=2-methylphenyl
and 4-chlorophenyl against Gram positive bacterial strains B. cocous and
B. subtillus. Significant activity was displayed by compounds bearing R=4-
methylphenyl, 4-methoxyphenyl 3-nitrophenyl and 4-bromophenyl.
While in case of Gram negative bacterial strains, highest activity was
displayed by compounds bearing R=4-methoxyphenyl and 4-fluorophenyl
against E. coli & P. vulgaris. Significant activity was observed in compounds
bearing R=phenyl, 2,3-dichlorophenyl and 3-chloro-4-fluorophenyl.
ANTIFUNGAL ACTIVITY
All the compounds were mild to moderately active against A. niger fungal
strain. Maximum activity was displayed by compound bearing R=2-methylphenyl.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoylpenicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
ANTITUBERCULAR ACTIVITY
All the compounds were found to be less active against Mycobacterium
tuberculosis H37Rv ranging from 3 to 41% inhibition.
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TABLE NO. 11a  : PRIMARY ASSAY OF ANTITUBERCULAR ACTIVITY
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N
N
F
NH
R
N
Dr. H. H. Parekh
Saurashtra University
TAACF, Southern Research Institute
Primary Assay Summary Report
295598 HCV-92 C
6
H
5
- Alamar H
37
Rv >6.25 0 - MIC Rifampin =
 0.25 µg/ml
@ 98% Inhibition
295599 HCV-93 4-OCH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 15 - "
295600 HCV-94 4-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 12 - "
295601 HCV-95 2-CH
3
-C
6
H
4
- Alamar H
37
Rv >6.25 23 - "
295602 HCV-96 4-Cl-C
6
H
4
- Alamar H
37
Rv >6.25 3 - "
295603 HCV-97 3-Cl-C
6
H
3
- Alamar H
37
Rv >6.25 4 - "
295604 HCV-98 4-F- C
6
H
4
- Alamar H
37
Rv >6.25 4 - "
295605 HCV-99 3/4-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 41 - "
295606 HCV-100 2/3-(Cl)
2
-C
6
H
3
- Alamar H
37
Rv >6.25 0 - "
295607 HCV-101 3-Cl,4-F--C
6
H
3
- Alamar H
37
Rv >6.25 8 - "
295608 HCV-102 3-NO
2
-C
6
H
4
- Alamar H
37
Rv >6.25 14 - "
295609 HCV-103 4-Br-C
6
H
4
- Alamar H
37
Rv >6.25 0 - "
Corp
ID
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ID
CommentAssay MTb
Strain
MIC
µg/ml
%
Inhib
Where,
R =
Activity
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  STUDIES ON
   MICROWAVE INDUCED
                     SYNTHESIS
INTRODUCTION OF PYRAZOLINES
See Part-I
MICROWAVE INDUCED SYNTHESIS
INTRODUCTION
In the last few years Microwave induced Organic Reaction Enhancement
(MORE) chemistry has gained popularity as a non-conventional technique for
rapid organic synthesis393 & many researchers have described accelerated organic
reaction and a large number of papers has appeared proving the synthetic utility
of MORE chemistry in routing organic synthesis. It can be termed as "e-chemistry'
because it is easy, effective, economical and eco-friendly and is believed to be a
step to-wards green chemistry.
Microwave assisted synthesis in general is likely to have a large impact on
synthetic organic chemistry in particular the medicinal/combinatorial chemistry
communities  compared to tradition processing of organic synthesis, microwave
enhanced chemistry saves significant time and very offen improves yields.
GENERAL PRINCIPLES
The microwave region of the electromagnetic spectum lies between 1 cm
and 1 m and in order to aviod interfering with radar and telecommunication
activities which operate within this region, most domestic and commercial
microwave instruments operate at 2.45 GHz. The heating effect utilised in
microwave assisted organic transformations is due in the main, to dielectric
polarisation, although conduction losses can be important particularly at higher
temperatures. Whilst the polarisability of a molecule (determined by the Debye
equation) is the sum of a number of contributions, only dipolar and interfacial
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polarisation are important to heating effects associated with microwave irradiation.
When a molecule is irradiated with microwaves it rotates to align itself with the
applied field. The frequency of molecular rotation is similar to the frequency of
microwave radiation and consequently the molecule continually attempts to
realign itself with the changing field and energy is absorbed. It is particularly
convenient that qualitatively, the larger the dielectric constant the great the
coupling with microwaves. Thus solvents such as water, methanol, DMF, ethyl
acetate, acetone, chloroform, acetic acid and dichloromethane are all heated when
irradiated with microwaves. Solvents such as hexane, toluene, diethyl ether, CCl4,
do not couple and therefore do not heat with microwave irradiation although it
is of course possible to use mixtures comprising microwave active/microwave
inactive solvents.
POWER SOURCES
The development of electron in tubes including those for the most microwave
range, has been a mature field. Today it is feasible to generate almost any desired
power level for microwave frequencies of practical interest limited only by cost.
Power sources in the millimeter wave range are mostly in the category of
extended interaction Klystrons or narrow band backward wave oscillators. They
are quite expensive and suffer from low life and efficiency. The most dramatic
evolution of a microwave power is one of the cooker magnetron for microwave
ovens. These tubes generate well over 700 Watt 2450 MHz into a matched load
and exhibit a tube efficiency on the order of 70%. It is feasible to utilize a number
of such tubes to generate large total power eq. 25 or 50 Kw.
APPLICATIONS IN ORGANIC SYNTHESIS
The first applications of microwave ovens in organic synthesis began very
recently. In the first experiments, Gedye394 and then Giguere395, provided
evidence for dramatic accelerations in some classical organic reactions and these
were ascribed to temperature and pressure effects, when performed in closed teflon
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vessels. Since solvents were used in these experiments, some problems with safe
operation appeared, and explosions sometimes resulted. Further developments
demonstrated the potential of solvent free reactions to solve these problems and
to facilitate the scale up of preparative runs.
Three types of solvent free procedures can be coupled with microwave
activation.
(i) reactions between heat reactants, needing at least one polar molecule, as
liquid-liquid or liquid solid systems. In this later case, reactions presumably
occur at the interface due to absoprtion of the liquid reactant at the surface
of the solid one.
(ii) Reactions between supported reagents on solid mineral supports in dry
media by impregnation of compounds on alumina, silicas or clays.
(iii) Phase Transfer Catalysis (PTC) conditions in the absence of organic solvent,
i.e. when a liquid reagent acts both as a reactant and an organic phase. This
last methodology can also be improved under sonochemical activation.
Microwaves constitutes very original procedure for heating materials, clearly
different from the classical ways. Their main adavntages derive from the almost
instantaneous "in core" heating of materials, in an homogeneous and selective
manner. Especially those with poor neat conduction properties. This technique
proves to be excellent in case where traditional heating has a low efficiency
because of poor heat transmission and hence local overheating is a major
inconvenience.
The main interests can thus be listed as the rapid transfer of energy into the
bulk of the reaction mixture, without inertia since only the products is heated
and the ease of utilization. Furthermore as the depth of penetration in materials
in of the same order of magnitude as the wavelengh, microwaves interact with
substance of appreciable thickness (about 10 cm).
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Microwave heating has emerged as a powerful technique to promote a variety
of chemical reactions.396 Microwave reaction under solvent-free conditions are
attractive in offering reduced pollution and offer low cost together with simplicity
in processing and handling397. The recent introduction of microwave synthesis
has gained acceptance and popularity among the synthetic chemist community
& it includes virtually all types of chemical reactions such as Diels-Alder398,
Claisen399, Vilsmeier400, Oxidation401, Substitution402,403, Cyclisation404,405,
Catalytic transfer hydrogenation406,407, Knoevenagel condensation408, oxime
synthesis409, alkylation410, decarboxylation411, etc.
Malhotra V. et. al.412 have demonstrated one-pot condensation of chalcones
with thiosemicarbazide in ethanol under strogly basic condensation. Microwave
enhanced esterification of α,β-unsaturated acids have been carried out by Kumar
Mitra & co-workers413. Microwave assisted fungicidal 1,2,4-traizines, 1,2,4-
tetrazoles, pyrazoles and triazoles have been synthesised by Mazahir Kidwai &
co-workers414.
Some other organic synthesis like 1,2-dihydropyridines415, phthalimide416,
& quinazolinone417 derivatives etc. also enhanced by the microwave irradiation.
Recently, microwave assisted some new organic reactions have been carried
out which include synthesis of pyrazolines418,419, isoxazoles420, cyano-
pyridines421, quinoxalines and heterocyclic pyrazines422, N-aryl phtalamic
acids423, substituted 2-pyridones424 and sulfonylbenzimidazole-4,7-diones425
with better biological activities.
As a part of ongoing research towards the non-traditional approach to the
experimental setup of organic reaction, the concept of microwave enhanced
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reaction has been utilised from rapid and efficient synthesis of 1,N-Acetyl-3-aryl-
5-[1',N-phenyl-3'-p-flurophenyl-pyrazol-4'-yl]-pyrazolines. Microwave oven is
used as a microwave irradiation source and compared in terms of yield and
reaction period and have been cited in Talbe No. 12a.
SECTION-I : SYNTHESIS OF 1,N-ACETYL-3-ARYL-5-[1 ' ,N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-
PYRAZOLINES USING CONVENTIONAL METHOD
SECTION-II : SYNTHESIS OF 1,N-ACETYL-3-ARYL-5- [1 ' ,N-
PHENYL-3'-p-FLUOROPHENYL PYRAZO-4'-YL]-
PYRAZOLINES USING MICROWAVE INDUCED
SYNTHESIS
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-
ARYL-5-(1 ' ,N-PHENYL-3 ' -p-FLUOROPHENYL PYRAZOL-4 ' -YL)-
PYRAZOLINE USING CONVENTIONAL METHOD
Looking to the interesting properties of pyrazolines, it was considered
worthwhile to synthesise a series of pyrazolines of type (IV) for obtaining
biologically potent agents which were prepared by reacting chalcones with
hydrazine hydrate in glacial acetic acid.
The constitution of the synthesised products have been characterised by
using elemental analyses, infrared and 1H nuclear magnetic resonance
spectroscopy and mass spectrometry also.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
The biological activities of the synthesised compounds were compared with
standard drugs.
R = ArylType - (XII)
N
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NH2.NH2.H2O
gl. CH3COOH
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IR SPECTRAL STUDY OF 1,N-ACETYL-3-(p-ANISYL)-5-(1 ' ,N-PHENYL-3' -p-
FLUOROPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
Instrument : SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range : 4000-400 cm-1 (KBr disc.)
Type
Vibration Frequency in cm-1      Ref.
mode  Observed   Reported
Alkane C – H str.(asym.) 2947 2975–2920 426
–CH
3
C – H str. (sym.) 2852 2880–2860 "
C – H i.p. (def.) 1454 1470–1435 "
C – H o.o.p. (def.) 1359 1385–1350 "
Aromatic C – H str. 3045 3080–3030 427
C – H i.p. (def.) 1089 1125–1090 "
1012 1070–1000 "
C – H.o.o.p (def.) 837 840–810 "
Pyrazole C = N str. 1596 1650–1585 428
moiety C = C str. 1546 1585–1480 "
C = N str. 1323 1350–1200 "
C – F 754 760–710 "
Ether C – O – C str. (asym.) 1213 1275–1200 "
C – O – C str. (sym.) 1062 1075–1020 "
Pyrazoline C = N str. 1596 1627–1580 429
C – H def. 686 698–680 "
C = O 1649 1760–1650 "
N
N F
N
N
O
CH3
OCH3
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PMR SPECTRAL STUDY OF 1,N-ACETYL-3'-(p-ANISYL)-5-(1',N-PHENYL-3'-p-
FLUOROPHENYL PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3   : Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (δ ppm) of Protons In Hz
1. 2.07 3H singlet COCH
3
-
2. 3.09-3.14 1H d. doublet CHh -
3. 3.61-3.71 1H d. doublet CHi -
4. 3.84 3H singlet Ar-OCH
3
-
5. 5.74-5.77 1H d. doublet CHj -
6. 6.90-6.93 2H doublet Ar-Hgg' Jgf=8.7
7. 7.09-7.15 2H triplet Ar-Hdd' -
8. 7.39-7.44 2H triplet Ar-Hbb' -
9. 7.59-7.62 2H doublet Ar-Hee' Jef=8.7
10. 7.68-7.71 2H doublet Ar-Hff' Jfg=7.9
11. 7.73-7.78 3H multiplet Ar-Hcc'+Ha -
12. 7.83 1H singlet CHx -
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EXPANDED AROMATIC REGION
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-
ARYL-5-(1 ' ,N-PHENYL-3 ' -p-FLUOROPHENYL PYRAZOL-4 ' -YL)-
PYRAZOLINE
[A] Synthesis  o f  N-Aminophenyl  α -methyl -α -p -f luorophenyl
azomethine
See, Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See, Part-I, Section-I (B).
[C] Synthesis of 1-(Anisyl)-3-(1'-N-phenyl-3'-p-fluorophenyl pyrazol-4'-
yl)-2-propene-1-one
See Part-I, Section-I (C).
[D] Synthesis  o f  1 ,N-Acety l -3- (p -anisy l ) -5 - (1 ' ,N-phenyl -3 ' -p -
fluorophenyl pyrazol-4'-yl) pyrazoline
To a mixture of 1-(p-Anisyl)-3-(1',N-phenyl-3'-p-fluorophenyl-pyrazole-4'-
yl)-2-propene-1-one (3.98g, 0.01M) in 25 ml of absolute alcohol add hydrazine
hydrate (0.5g, 0.01M) and glacial acetic acid 10 ml added, the contents were
refluxed for 10 hrs. at temp 120oC. and poured into ice. The product was isolated
and crystallised from ethanol. Yield 70% m.p. 200oC (C27H23FN4O2 ; Found :
C, 71.31%; H, 5.06%; N, 12.28%; Requires : C, 71.35%; H, 5.10%; N, 12.33%).
Similarly other substituted pyrazolines have been prepared. The physical
data are recorded in Total No. 12.
(E) Antimicrobial activity of 1,N-Acetyl-3-aryl-5-(1',N-phenyl-3'-p-
fluorophenyl-pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I(D).
The zone of inhibition of the test solutions are recorded in Graphical Chart No. 12.
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TABLE NO.12 : PHYSICAL CONSTANTS OF 1,N-ACETYL-5-ARYL-3-(1',N-PHENYL-3'-p-FLUOROPHENYL-
PYRAZOL-4'-YL)-PYRAZOLINES
Sr.
No.
1
12a C6H5- C26H21FN4O 424 220 0.49 60 13.20 13.14
12b 4-OCH3-C6H4- C27C23FN4O2 454 200 0.56 70 12.33 12.28
12c 4-CH3-C6H4- C27H20FN4O2 454 234 0.39 65 12.78 12.71
12d 4-Cl-C6H4- C26H20ClFN4O 458 240 0.47 71 12.21 12.15
12e 4-F-C6H4- C26H20F2N4O 442 216 0.73 70 12.66 12.61
12f 4-OH-C6H4- C26H21FN4O2 440 258 0.52 64 12.72 12.73
12g 2-OH-C6H4- C26H21FN4O2 440 212 0.62 66 12.72 12.71
12h 4-NO2-C6H4- C26H20FN5O3 469 138 0.66 75 14.92 14.88
12i 3-NO2-C6H4- C26H20FN5O3 469 160 0.48 62 14.92 14.85
12j 4-Br-C6H4- C26H20BrFN4O 503 230 0.78 68 11.13 11.08
12k 4-NH2-C6H4- C26H22FN5O 439 187 0.43 64 15.94 15.90
12l C4H3S- C24H19FN4SO 430 207 0.59 72 13.01 12.95
*TLC Solvent System : Ethyl acetate : Hexane
1 : 9 (4c, 4k)
2 : 8 (4a-4b, 4d-4j, 4l)
Rf*
Value
6
Yield
%
7
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Formula
3
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SECTION-II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-ACETYL-3-
ARYL-5-[1 ' ,N-PHENYL-3 ' -p-FLUOROPHENYL-PYRAZOL-4 ' -YL]-
PYRAZOLINES USING MICROWAVE INDUCED SYNTHESIS
EXPERIMENTAL
A mix of 1-anisyl-3-(1',N-phenyl-3'-p-f luorophenyl-pyrazol-4'-yl)-2-
propene-1-one (3.98g, 0.01M), hydrazine hydrate (0.5g, 0.01M) and glacial acetic
acid (15 ml) was irradiated in a Q-Pro-M Microwave oven (220 VAC, 60Hz)
[Questron Technologies Corporation-CANADA] at temp. 120oC for 9 min. under
power level of 40% taking care not to heat the contents longer than 2 min at a
time to avoid boiling off the reaction mixture. The contents were cooled and
poured into ice cold. water. product was isolated & crystallised from ethanol,
yield 74%, m.p. 201oC. (C27H23FN4O2 Found : C, 71.31%; H, 5.06%; N,12.28%;
Requires : C, 71.35%; H, 5.10%; n, 12.33%)
Similarly other substituted pyrazolines have been prepared.
The constitution of the synthesised products have been characterised by
using elements have been characterised by using elemental analyses, infrared
and 1H nuclear spectrometry.
The synthesised products have been screened for their in vitro biological
assay like antibacterial activity towards Gram positive & Gram negative bacterial
strians and antifungal activity to wards Aspergillus niger at a concentration of
40 mg/ml. The biological activities of synthesised compounds were compared
with standard drugs.
Comparision of the convention and microwave induced synthesis of
pyrazolines in terms of yield and reaction preiod have been eited in Table
No. 12a.
191
TABLE NO. 12a : COMPARISION OF CONVENTIONAL AND MICROWAVE
ENHANCED SYNTHESIS OF PYRAZOLINES
12a C6H5- 10 60 9 63 220
12b 4-OCH3-C6H4- 10 70 10 72 200
12c 4-CH3-C6H4- 10 65 9 68 234
12d 4-Cl-C6H4- 10 71 9 73 240
12e 4-F-C6H4- 10 70 8 72 216
12f 4-OH-C6H4- 10 64 9 66 258
12g 2-OH-C6H4- 10 66 10 69 212
12h 4-NO2-C6H4- 10 75 7 77 138
12i 3-NO2-C6H4- 10 62 9 64 160
12j 4-Br-C6H4- 10 68 9 70 230
12k 4-NH2-C6H4- 10 64 8 67 187
12l C4H3S- 10 72 7 74 207
Comp.
No.
ThermalR Microwave
Reaction
Period (hr.)
Yield
%
Reaction
Period (min.)
Yield
%
M.P.
oC
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  GRAPHYCAL CHART NO.12: ANTIMICROBIAL ACTIVITY OF1,N-ACETYL-3-ARYL-5-[1’N-PHE NYL- 3’-p-FLUOROPHENYL PYRAZOL-4’-YL]
-PYRAZOLINES.
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B. cocous 18 16 13 12 10 11 17 18 9 16 13 11 17 21 16 23 0
B. subtillus 11 19 21 18 17 11 10 12 21 13 16 9 15 21 22 19 0
E. coli 21 19 10 18 16 13 12 10 17 14 11 10 19 18 20 22 0
P. vulgaris 18 10 11 19 18 17 10 13 13 13 16 9 16 19 15 21 0
A. niger 18 17 14 15 18 19 13 12 14 11 10 18 0 0 0 0 26
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CONCLUSION
ANTIBACTERIAL ACTIVITY
From the experimental data, it was revealed that most of acetyl pyrazoline
derivatives (type-XII), were able to inhibit the growth of Gram positive and Gram
negative bacterial strains.
It has been observed that maximum activity was displayed by the compounds
bearing R=phenyl, 4-methoxyphenyl and 3-nitrophenyl against Gram positive
bacterial strains B. Cocous and B. Subtillus. While significant activity was
displayed by the compound bearing R=4-nitrophenyl, 2-hydroxyphenyl and
thienyl against these Gram positive bacterial strains.
While in case of Gram negative bacterial strains, maximum activity was
displayed by compounds bearing R=phenyl & 4-chlorophenyl against E. Coli
& P. Vulgaris. While significant activity was observed in compounds bearing
R=4-methoxyphenyl, 4-fluorophenyl & 4-aminophenyl against these Gram
positive bacterial strains.
ANTIFUNGAL ACTIVITY
All the compounds were less active against fungal strain A. niger.
The antimicrobial activity shown by compounds was compared with known
antibiotics like Amoxycillin, Benzoyl Penicillin, Ciprofloxacin, Erythromycin &
Greseofulvin.
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